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Commit to the Lord whatever you do, and all your plans will succeed.
    Proverb 16:3   
 
 
 
If I have seen further than others, it is by standing upon the shoulders 
of giants.         
   Issac Newton, Father of Modern Science. 1642-1727. 
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Summary 
 The vascular endothelium plays an important role in the maintenance of normal 
cardiovascular functions. It prevents smooth muscle contraction, inhibits smooth muscle cell 
proliferation and /or migration and exerts anti-thrombotic effects. One of the most important 
factors derived from endothelial cells is nitric oxide (NO) which is produced via activation of 
endothelial NO synthase (eNOS). eNOS metabolizes the substrate L–arginine to NO in the 
presence of co-factors under physiological conditions. However, under disease conditions, 
such as atherosclerosis, diabetes, hypertension, aging, etc., NO bioavailability is decreased, 
which is implicated in initiation and evolution of the disease process. The decreased NO 
bioavailability is either attributed to a decreased eNOS gene expression or decrease in enzyme 
activity or inactivation of bioactive NO by oxidative stress.  
RhoGTPase is a member of the Ras superfamily of small GTP-binding proteins which 
is not only involved in regulation of cellular functions associated with cytoskeleton 
reorganisation such as platelet aggregation, smooth muscle contraction  and cell migration, 
but also in regulation of gene expression. Studies in recent years demonstrate that RhoA 
suppresses eNOS gene expression in endothelial cells by destabilizing eNOS mRNA. 
Inhibition of RhoA by the HMG-CoA reductase inhibitors or statins upregulates eNOS 
expression. These may importantly contribute to the beneficial effects of the drugs in patients 
with coronary heart diseases.  
In the first part of the project we further confirmed the role of the RhoGTPase, RhoA 
in down-regulation of eNOS gene expression in human endothelial cells. This effect is 
mediated by down-stream effector Rho-kinase (ROCK). Most importantly, we established a 
role of RhoA/ROCK pathway in inhibition of Akt/eNOS cascade, i.e. activation of 
RhoA/ROCK inhibits PKB/Akt activity and subsequently activation or phosphorylation of 
eNOS at S-1177.  
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In the second part of the project we explored another important role of Rho/ROCK 
pathway in regulation of eNOS activity namely stimulation of arginase in endothelial cells. 
Arginase competes with eNOS for the substrate L-arginine. It metabolizes L-arginine to urea, 
thus depletes intracellular L-arginine for NO production. We showed that overexpression of 
RhoA or ROCK active mutants enhances arginase activity in endothelial cells. Interestingly, 
in ApoEP-/-P atherosclerotic mice aorta, RhoA expression was much more pronounced as 
compared to the wild type animals, which is correlated with a higher arginase activity in 
ApoEP-/-P mice aortas. In atherosclerotic ApoEP-/-P mice aortas, L-arginine caused a more 
pronounced contraction as compared to wild type mice. This response was reversed to a 
greater relaxation by an arginase inhibitor L-norvaline in ApoEP-/- Pmice compared to the wild 
type animals. The results demonstrate that an increased arginase activity mediated by 
Rho/ROCK pathway is involved atherosclerotic endothelial dysfunction. 
In the third part of the project, we demonstrated that Rho/ROCK pathway together 
with p38 Pmapk P increases expression of endothelial tissue factor which is critical in thrombus 
formation and acute coronary syndromes. In this part of the project, we showed that high 
density lipoprotein (HDL) on one hand activates PI3K/Akt/eNOS pathway and on the other 
hand inhibits tissue factor expression. The inhibition of endothelial tissue factor expression by 
HDL is mediated through inhibition of RhoA and activation of PI3K, independent of the 
downstream enzymes, Akt/eNOS. Taken together, our results demonstrate multi-functional 
roles of Rho/ROCK pathway in endothelial dysfunction, which may be importantly involved 
in the pathogenesis of cardiovascular disease. 
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Zusammenfassung 
Das Gefässendothel spielt eine wichtige Rolle bei der Aufrechterhaltung normaler 
kardiovaskulärer Funktionen. Es verhindert die Kontraktion glatter Muskulatur, hemmt die 
Proliferation und/oder Migration der glatten Muskelzellen und übt eine antithrombotische 
Wirkung aus. Einer der wichtigsten Faktoren endothelialer Herkunft ist Stickstoffmonooxid 
(NO), das durch Aktivierung der endothelialen NO-Synthase (eNOS) produziert wird. eNOS 
setzt als Substrat L-Arginin unter physiologischen Bedingungen und in Anwesenheit von 
Cofaktoren zu NO um. Im Verlauf bestimmter Krankheiten, z.B. bei Arteriosklerose, Diabetes 
und Bluthochdruck, oder im Alter ist die biologische Verfügbarkeit von NO jedoch verringert, 
was mit der Entstehung und dem Fortschreiten dieser Prozesse in Verbindung gebracht wird. 
Diese verringerte biologische Verfügbarkeit von NO wird entweder auf eine geringere eNOS-
Expression oder einen Rückgang der Enzymaktivität bzw. eine Inaktivierung von aktivem NO 
durch oxidativen Stress zurückgeführt. 
Die RhoGTPase ist ein Mitglied der Ras-Superfamilie kleiner GTP-bindender 
Proteine. Sie ist nicht nur an der Regulation mit Cytoskelettreorganisation verbundener 
zellulärer Prozesse wie Blutplättchenaggregation, Kontraktion glatter Muskulatur und 
Zellmigration, sondern auch an den Regulation der Genexpression beteiligt. In den letzten 
Jahren haben Studien ergeben, dass RhoA eNOS-Expression in endothelialen Zellen durch 
Destabilisierung der eNOS-mRNA unterdrückt. Hemmung von RhoA durch HMG-CoA-
Reduktaseinhibitoren oder Statine erhöht eNOS-Expression. Dies kann zu den positiven 
Effekten der Medikation bei Patienten mit koronarer Herzkrankheit beitragen. 
Im ersten Teil des Projekts haben wir die Rolle der RhoGTPase RhoA bei der 
Herunterregulierung der eNOS-Expression in menschlichen Endothelzellen bestätigt. Diese 
Wirkung wird durch den Effektor Rho-Kinase (ROCK) vermittelt. Insbesondere haben wir 
eine Beteiligung des RhoA/ROCK-Signalwegs an der Hemmung der Akt/eNOS-Kaskade 
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nachgewiesen, d.h., die Aktivierung von RhoA/ROCK hemmt PKB/Akt-Aktivität und 
verhindert infolgedessen Aktivierung oder Phosphorylierung von eNOS an S-1177. 
Im zweiten Teil des Projekts haben wir eine weitere wichtige Funktion des 
RhoA/ROCK-Signalwegs in der Regulation der eNOS-Aktivität, die Stimulation des Enzyms 
Arginase in Endothelzellen, untersucht. Die Arginase setzt L-Arginin zu Harnstoff um, 
wodurch intrazelluläres L-Arginin, das für die NO-Bildung eingesetzt wird, abgezogen wird. 
Wir konnten zeigen, dass die Ueberexpression aktiver Formen von RhoA oder ROCK die 
Arginaseaktivität in Endothelzellen erhöht. Interessanterweise war die RhoA-Expression in 
den Aortae arteriosklerotischer ApoEP-/-P- Mäuse deutlich höher als in denen der Wildtyp-
Mäusen. Dies korrelierte mit einer erhöhten Arginaseaktivität in den ApoE-/- Mäusen. In den 
Aortae der arteriosklerotischen Mäuse rief L-Arginin eine stärkere Kontraktion als in denen 
der Wildtyp-Mäuse hervor. Diese Reaktion wurde bei Behandlung mit dem Arginaseinhibitor 
L-Norvalin in eine stärkere Relaxation der ApoEP-/-P-Aortae gegenüber den Wildtypgefässen 
umgekehrt. Diese Ergebnisse zeigen, dass die durch den RhoA/ROCK-Signalweg erhöhte 
Arginaseaktivität an arteriosklerotischer Fehlfunktion des Endothels beteiligt ist. 
Im dritten Teil des Projekts konnten wir nachweisen, dass der RhoA/ROCK-
Signalweg zusammen mit p38Pmapk P die Expression des endothelialen Tissue-Faktors erhöht. 
Tissue-Faktor ist kritisch für die Gerrinselbildung und spielt eine wichtige Rollen bei akuten 
koronaren Symptomen. In diesem Teil des Projekts zeigten unsere Resultate, dass das High-
Density-Lipoprotein (HDL) einerseits den PI3K/Akt/eNOS-Signalweg aktiviert und 
andererseits die Expression des Tissue-Faktors hemmt. Die Hemmung der Expression des 
endothelialen Tissue-Faktors durch HDL ist auf zwei Mechanismen zurückzuführen: 
Hemmung von RhoA und Aktivierung der PI3K, wobei die weiter abwärts im PI3K-
Signalweg liegenden Enzyme Akt und eNOS nicht involviert sind. 
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Zusammenfassend demonstrieren unsere Ergebnisse eine multifunktionelle 
Beteiligung des RhoA/ROCK-Signalwegs an endothelialer Fehlfunktion. Dies spielt 
möglicherweise eine wichtige Rolle bei der Pathogenese kardiovaskulärer Erkrankungen. 
________________________________________________________________________Introduction 
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I. INTRODUCTION 
1. THE CARDIOVASCULAR CIRCULATION SYSTEM: OVERVIEW 
 In the 17th century, the English physician William Harvey (Figure 1A) 
demonstrated that all venous blood moves from the periphery of the body to a single 
center, the heart which acted as a pump forcing blood to the periphery of the body 
through arteries and returning it to the heart through veins and was recycled. Harvey’s 
discovery led to the basic knowledge of the cardiovascular system as a closed loop in 
which blood is circulating. 
 
Figure 1: (A) William Harvey (1578 – 1657). (B) The pulmonary circulation and the systemic    
circulation. 
The heart pumps blood through two separate vascular systems, one to the lung, 
the low pressure pulmonary circulation in which gas exchange occurs, and one to all 
other organs of the body, the systemic circulation, which delivers blood to individual 
organs, matching supply to metabolic demand (Figure 1B). Arteries branch and 
diverge as they move away from the heart. As they form smaller and smaller 
 B.A
________________________________________________________________________Introduction 
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divisions, they become a meshwork of capillaries. The veins channel blood from 
capillaries back to the heart. The capillary meshwork is the site of gas, nutrient and 
waste exchange between the blood and the respirating tissues. It is the connecting site 
of arteries and veins, which William Harvey could not see by eye. 
2.  THE VASCULAR ENDOTHELIUM: IMPORTANT MODULATOR OF 
CARDIOVASCULAR FUNCTION 
The blood flow to individual organs is tightly regulated by neuronal and 
hormonal factors (Table 1). For example, the sympathetic nervous activity stimulates 
cardiac function and vasoconstriction by releasing neurotransmitter catecholamines 
i.e. noradrenaline and adrenaline from the synaptic endings via activation of 
adrenergic β-1 in the heart and α-1 receptors on vascular smooth muscle cells (SMC). 
The effects of the sympathetic nervous activity are counteracted by parasympathetic 
nervous system via neurotransmitter, acetylcholine. Moreover, circulating hormones 
including vasoconstrictors (i.e. angiotensin II, serotonin, vasopressin etc.) and 
vasodilators (i.e. ANP, bradykinin, adenosine etc.) also play important roles in the 
regulation of blood flow to organs (Table 1). 
Vasoconstriction Vasorelaxation 
Sympathetic Nervous System Parasympathetic Nervous System 
Angiotensin II Atrial natriuretic peptide (ANP) 
Serotonin Adenosine 
Vasopressin Bradykinin 
Endothelin-1 Prostacyclin 
Thromboxanes Adrenomedullin 
Table 1:  A vast list of various vasoactive factors are known to regulate blood flow to the organs. 
The list is growing steadily. 
________________________________________________________________________Introduction 
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Research in the past two decades provides firm evidence demonstrating that 
the monolayer of the endothelium is not only a simple diffusion barrier between the 
intravascular and extravascular space of blood and lymph vessels, but also an active 
organ synthesizing, releasing and metabolizing various vasoactive hormones (Figure 
2, Figure 3). A number of relaxing and contracting factors derived from the 
endothelium have been characterized (Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2: The endothelium as an active organ releases various vasoactive substances including 
relaxing and contracting factors.  The endothelium-derived relaxing factors shown on the right 
relax smooth muscle; inhibit cell proliferation and platelet aggregation via second messengers 
(cGMP or cAMP) or via opening of KP+P-channels. The endothelium-derived contracting factors 
shown on the left cause smooth muscle contractions stimulate cell proliferation or platelet 
aggregation. The production of contarcting factors could be inhibited by relaxing factors under 
physiological conditions. TXAB2B/PGHB2B = thromboxane AB2 B/prostaglandin HB2 B, ET-1 = endothelin-1, 
CNP = C-type natriuretic peptide, NO = nitric oxide, Adm = adrenomodulin, PGIB2B = 
prostaglandin IB2B, EDHF = endothelium-derived hyperpolarizing factor, cGMP = cyclic guanosine 
monophosphate, cAMP = cyclic adenosine monophosphate, UII = urotensin II, EC = endothelial 
cell, SMC = smooth muscle cell,   +    stimulation,  -   inhibition.  
 
TXA2/PGH2
Contraction/Proliferation
ET-1 NO Adm PGI2 EDHF
cAMPcGMP
Relaxation /Anti-Proliferation
Relaxing FactorsContracting Factors
CNP 
K+-Channel
-
+
Platelets
EC
SMC
-
 cGMP/cAMP 
 UII 
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Figure 3: Activation and inactivation of vasoactive hormones by endothelial cells: Endothelial 
cells express endothelin-converting enzyme (ECE) and angiotensin-converting enzyme (ACE) 
which converts big-ET-1 and angiotensin I into active ET-1 and angiotensin II, respectively 
causing potent vasoconstriction and promoting smooth muscle cell growth. Endothelial cells also 
express neutral endopeptidase (NEP) which inactivates various vasoactive substances known to 
release NO or PGI2. Combined inhibitors of NEP, ACE and/or ECE demonstrate a powerfull 
strategy to improve endothelial function. ETBA B/ETBBB=endothelin receptors, AT1=angiotensin 
receptor type 1, eNOS= endothelial nitric oxide synthase, cGMP= cyclic guanosine 
monophosphate. 
The vascular endothelium is also an important source of thrombogenic and 
anti-thrombogenic factors which regulate platelet-vessel wall interaction. Finally, it 
directly (by producing growth promoters and inhibitors) or indirectly (by inhibiting 
activation of platelets which are rich in growth factors for SMC) modulates SMC 
migration and proliferation (Figure 2). The multiple functions of the endothelium 
under physiological conditions are summarized in Figure 4. However, under 
pathological conditions, an imbalance between these factors occurs as a result 
contracting factors, thrombogenic factors and growth promoters become dominant. 
Among them, endothelial nitric oxide (NO) is one of the most important factors 
in the regulation of vascular homeostasis. 
Contraction/Proliferation
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Relaxation/Anti-Proliferation
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Figure 4: The healthy endothelium not only mediates endothelium-dependent vasodilation, but 
also actively suppresses thrombosis, vascular inflammation, and hypertrophy (from Landmesser 
U, Circulation. 2004;109, Suppl 1:II27-33). 
2.1 The Discovery of Endothelium-Derived NO 
In 1978, the group of Murad demonstrated that the vasodilatory effects of 
nitroglycerine and other nitrates (that had been used for decades to treat patients with 
angina pectoris without knowing their mechanism of action) were mediated by a 
common degradation product, NO with a very short half life of 3-5 seconds. This 
class of compounds causes vascular relaxation via activation of soluble guanylyl 
cyclase in SMC of blood vessels. 
In 1980, Furchgott observed that relaxations evoked by acetylcholine (ACh) in 
rabbit aorta and other arteries require an intact endothelial layer (Furchgott et al., 
1980). Indeed, in arteries, in which the endothelium was gently removed either 
mechanically or enzymatically, the relaxations in response to ACh were absent 
(Figure 5). With a simple but elegant so-called ‘sandwich preparation’ bioassay, a 
layering of two strips of arteries with (sandwiched) and without endothelial layer 
between the strips (Figure 5), Furchgott demonstrated convincingly that the 
relaxations induced by ACh in the arteries are mediated by a diffusable relaxing 
Healthy endothelium
Anti-inflammatory
(Inhibition of leukocyte adhesion
and migration)
Antithrombotic
(Inhibition of platelet adhesion
and aggregation)
Anticoagulant/
Profibrinolytic
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substance(s) produced by the endothelium. This factor(s) was named endothelium-
derived relaxation factor (EDRF). 
 
 
 
 
 
 
 
Figure 5: Robert F Furchgott showed that acetylcholine-induced relaxation of blood vessels was 
dependent on the endothelium. His "sandwich" experiment set the stage for future scientific 
development. He used two different pieces of the aorta; one had the endothelial layer intact, in 
the other it had been removed. NA = Noradrenaline. (from Furchgott RF, Nature. 1980. 288:373-
6). 
Within a few years, this observation was expanded to different species 
including vertebrates, bony fish and amphibia, mammals and humans in different 
vascular beds, suggesting an ancestoral phenomenon preserved during evolution. 
During the following years, it appeared that there were chemical similarities 
between NO and EDRF. Besides, both compounds exerted vasodilation by means of 
cyclic GMP synthesis. Finally, the group of Ignarro proposed in 1987 that EDRF was 
nitric oxide (Ignarro et al., 1987). Soon, the group of Moncada (1987) obtained the 
first results supporting that proposal (Palmer et al., 1987). They demonstrated that 
endothelial cells produce NO in sufficient amounts to explain the relaxation observed 
(Radomski et al., 1987; Ignarro et al., 1987) and that nitric oxide is produced from 
the precursor, L-arginine via endothelial nitric oxide synthase (eNOS) (Figure 6).  
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Figure 6: Endothelial L-arginine /NO pathway. (Abbr: EC = endothelial cells, SMC = smooth 
muscle cells,  -  inhibition) 
For the discovery of endothelial L-arginine/NO pathway Drs. Furchgott, Murad and 
Ignarro were awarded the 1998 Nobel Prize in Medicine and Physiology (Figure 7). 
 
Figure 7: RF Furchgott, F Murad and LJ Ignarro: Nobel Laureates in Medicine and Physiology, 
1998. 
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2.2 Functions of Endothelial NO 
In cardiovascular system, NO is an important determinant of basal vascular 
tone, prevents platelet activation, limits leukocyte adhesion to the endothelium, 
regulates myocardial contractility and inhibits SMC migration and proliferation 
(Figure 6). Overproduction of NO plays a role in cardiovascular disorders, such as 
septic shock (Isobe et al., 2001) and in a major portion of neural damage following 
vascular stroke (Rao et al., 1999). Decreased NO function is involved in the 
pathogenesis of many cardiovascular disorders such as hypertension, atherosclerosis, 
venous bypass graft disease, diabetic vascular disease etc. (see 2.3). 
2.3 Risk Factors for Endothelial Dysfunction 
As mentioned above, endothelial dysfunction, represented as impaired 
function of endothelial L-arginine/NO pathway is a common mechanism for various 
cardiovascular disorders. In the past years, a vast list of risk factors for cardiovascular 
disease has been reported to cause endothelial dysfunction (Figure 8). 
 
 
 
 
 
 
 
Figure 8: Risk factors that impair endothelial function. 
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2.4 Regulatory mechanism of endothelial L-arginine/NO pathway 
The underlying mechanisms of endothelial dysfunction caused by the risk 
factors could be summarized at three different levels (Figure 9): (1) regulation of 
eNOS gene expression (2) regulation of eNOS enzyme activity and (3) regulation of 
NO bioavailability. 
 
 
 
 
 
Figure 9: Regulatory mechanism of endothelial L-arginine/NO pathway. (Abbr: TNFα = tumor 
necrosis factor-α, BHB4B = tetrahydrobiopterin, VEGF = vascular endothelial growth factor, ox-
LDL = oxidized LDL,  -  = inhibition,  +  = stimulation) 
2.4.1. Regulation of eNOS gene expression  
Three isoforms of eNOS could be distinguished: NOS1 (also named as 
neuronal NOS, nNOS, or NOS I), NOS2 (inducible NOS, iNOS, or NOS II), and 
finally NOS3 (endothelial NOS, eNOS, or NOS III) (Forstermann et al., 1995) (Table 
2). All these subtypes use L-arginine as substrates and oxygen, NADPH, FMN, FAD, 
tetrahydrobiopterin and heme as cofactors to produce NO. Although, NOS1 was 
initially found in the brain, NOS2 in macrophages and NOS3 in the endothelium, they 
have later been found in many other cells of the organism with different level of 
expressions. Some of the important characteristics of NOS isoforms are summarized 
in Table 2. 
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Human NOS Cell Types Size Subcellular 
Site 
Regulation of 
activity 
NO 
output 
Co-
factors 
Constitutive 
neuronal 
(nNOS, 
NOS1) 
Neuronal, 
skeletal 
muscle cells, 
cardiac muscle 
cells 
161 
kDa 
Cytosol Regulatable Low 
(pM) 
BHB4 B, 
NADPH, 
FAD, 
FMN, 
heme 
Constitutive, 
endothelial 
(eNOS, 
NOS3) 
Endothelial 
cells 
133 
kDa 
Membrane>
>cytosol 
Regulatable Low 
(pM) 
BHB4 B, 
NADPH, 
FAD, 
FMN, 
heme 
Inducible 
NOS (iNOS, 
NOS2) 
Macrophage,
many other 
cell types 
131 
kDa 
Cytosol>> 
Membrane 
Non-regulatable High 
(µM) 
BHB4 B, 
NADPH, 
FAD, 
FMN, 
heme 
Table 2: Characteristics of different isoforms of nitric oxide synthase. Abbr: BHB4B = 
tetrahydrobiopterin, NADPH = nicotinamide adenine dinucleotide phosphate reduced, FAD = 
flavin adenine dinucleotide, FMN = flavin mononucleotide.  
eNOS was originally proposed as a constitutively expressed enzyme in 
vascular endothelial cells. However, studies in the past provide evidence that the 
expression level of eNOS could be regulated by several mechanisms. mRNA levels 
represent the balance between gene transcription and mRNA degradation. The 
kinetics of mRNA degradation is dependent partly, on nucleotide sequence motifs, 
which are usually located in the 3' untranslated region of the gene. Possible 
interactions of specific proteins to these sequences may render the mRNA more or 
less susceptible to endonucleolytic cleavage. Two motifs often implicated in mRNA 
destabilization are present at the 3' end of the eNOS mRNA (Marsden et al., 1993). In 
accordance, some stimuli affect eNOS mRNA stability. TNF-α destabilizes eNOS 
mRNA, which is suggested to be mediated by the increased binding of regulatory 
cytosolic proteins to the 3' untranslated region of the eNOS mRNA (Alonso et al., 
1997). Other stimuli that have been reported to decrease eNOS mRNA stability 
include lipopolysaccharides (endotoxins) (Lu et al., 1996), hypoxia (Michel et al., 
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1997), and oxidized LDL (Liao et al., 1995). Such mechanisms could also be 
involved in decreased eNOS expression in inflammatory models of renal injury such 
as necrotizing crescentic glomerulonephritis (Heeringa et al., 1998). On the other 
hand, certain conditions of shear stress upregulate eNOS mRNA levels through 
posttranscriptional events (Ziegler et al., 1998). VEGF- as well as hydrogen 
peroxide-induced eNOS upregulation is also dependent on an enhanced stability of 
eNOS mRNA. Thus, eNOS expression is affected by various stimuli, which modify 
eNOS regulation at the mRNA level by inducing changes in transcription kinetics and 
stability of the eNOS mRNA. 
2.4.2. Regulation of eNOS Enzymatic Activity 
Co-factors 
eNOS consists of a flavin-containing reductase domain and a heme-containing 
oxidase domain. NADPH reduces the flavin component of the reductase domain, but 
electron transfer to heme will not occur until Ca P2+ P/calmodulin is present (Craig et al., 
2002). In the presence of CaP2+P/calmodulin, there is an electron transfer from NADPH 
to the heme group. In the presence of L-arginine, electrons flow to the heme moiety to 
reduce oxygen which is used to oxidize L-arginine to NO and citrulline. Another 
cofactor, tetrahydrobiopterin or BH B4 B, has been postulated to play an important role in 
whether the electron flow in the enzyme can be directed to L-arginine (Heitzer et al., 
2000; Shinozaki et al., 1999). Indeed, in the (neural) NOS I isoform or nNOS, 
depletion of BHB4 B results in uncoupling of oxygen reduction and arginine oxidation, 
thereby generating superoxide and subsequently hydrogen peroxide. Regarding 
recombinant eNOS, it is confirmed that addition of BHB4 B increases NO production and 
reduces superoxide generation by eNOS (Xia et al., 1998). The exact mechanisms by 
which BHB4 B exerts these effects are not known. In nNOS, BHB4 B appears to play a major 
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role in stabilizing the NOS in its active dimeric form (Noguchi et al., 2001). However, 
this allosteric role of BH B4 B appears to be less prominent for recombinant eNOS.  
Protein-protein Interactions 
Considerable attention has been paid to the mechanisms by which the 
localization of eNOS to caveolae affects the function of the enzyme, including the 
interaction of eNOS with other resident proteins such as the caveolae coat protein, 
caveolin. 
In vitro studies and experiments with eNOS and caveolin-1 overexpression in 
COS-7 cells revealed that both N- and C-terminal domains of caveolin interact 
directly with the eNOS oxygenase domain and inhibit eNOS catalytic activity (Ju et 
al., 1997; Michel et al., 1997). In vitro manipulations further indicated that CaP2+P-
calmodulin may disrupt the interaction between eNOS and caveolin, leading to 
enhanced enzymatic activity (Michel et al., 1997). N-myristoylation and post-
translational palmitoylation target newly synthesized eNOS to the caveolae. Agonist-
induced activation of eNOS is accompanied by depalmitoylation mediated via a 
calcium/calmodulin dependent acyl hydrolase. Re-formation of the caveolin-1/eNOS 
heterodimer is facilitated by re-palmitoylation, by a process that remains poorly 
understood (Weis et al., 2004).  
Bucci et al. demonstrated that a chimeric peptide with a cellular internalization 
sequence fused to the caveolin-1 scaffolding domain was efficiently incorporated into 
blood vessels and endothelial cells, resulting in selective inhibition of acetylcholine-
induced vasodilation and NO production (Bucci et al., 2000). Caveolin-1-deficient 
mice moreover, demonstrated a higher eNOS activity when eNOS signalling was 
measured by monitoring the response of aortic rings to various stimuli. They also 
have a loss of caveolin-2 protein expression, defects in the endocytosis of a known 
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caveolar ligand, i.e. fluorescein isothiocyanate-albumin and a hyperproliferative 
phenotype. Caveolin-1-deficient mouse smooth muscle cells proliferated 
approximately 2-fold faster and to higher saturation densities than their wild-type 
counterparts (Hassan et al., 2004). The reason to this observation is still to be 
investigated. Importantly, these phenotypic changes are reversed by recombinant 
expression of the caveolin-1 cDNA, indicating that caveolin-1 expression is required 
to stabilize the caveolin-2 protein product, to mediate the caveolar endocytosis of 
specific ligands, to negatively regulate the proliferation of certain cell types and to 
provide tonic inhibition of eNOS activity in endothelial cells (Razani et al., 2001). 
There is also evidence of other protein-protein interactions that modify eNOS 
function. Ju and colleagues have demonstrated that the activity of the enzyme is 
negatively regulated by its association with the C-terminal domain of G protein-
coupled receptors such as the bradykinin B2 receptor, which is mobilized to the 
caveolae upon agonist stimulation (Ju et al., 1998). B2 receptors are coupled to the 
activation of recombinant eNOS expressed in adventitial fibroblasts (Tsutsui et al., 
2000). In addition, stimulation of endothelial cells by histamine, vascular endothelial 
growth factor (VEGF), or shear stress leads to the binding of heat shock protein 90 
(hsp90) to eNOS, which causes allosteric activation of the enzyme (Brouet et al., 
2001). Furthermore, yeast two-hybrid screening has recently identified a novel 34-
kDa protein designated NOSIP (eNOS interacting protein) that binds to the C-
terminal region of the eNOS oxygenase domain and promotes translocation of the 
enzyme from caveolae to intracellular sites, resulting in the attenuation of NO 
production (Dedio et al., 2001) 
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Post-translational Regulation 
In addition to modulation by protein-protein interaction, multiple signal 
transduction pathways converge to regulate eNOS by a phosphorylation process. 
The activation of the enzyme in response to multiple hormone agonists such as 
estradiol, bradykinin and VEGF occurs in association with elevations in cytosolic 
calcium concentrations (Goetz et al., 1999; Prabhakar et al., 1998; Papapetropoulos et 
al., 1997). In contrast, eNOS activation by shear stress and isometric vessel 
contraction occurs independently of changes in intracellular calcium levels 
(Fisslthaler et al., 2000; Fleming et al., 1999). Shear stress-induced enzyme activation 
is regulated by potassium channels, and it is prevented by tyrosine kinase inhibition, 
indicating that the process also entails tyrosine phosphorylation (Fleming et al., 1998; 
Fleming et al., 1997; Thorsgaard et al., 2003).  
In addition to regulation by calcium and via tyrosine phosphorylation, multiple 
protein kinases modify eNOS activity through effects on serine phosphorylation at 
position 1177 in human endothelial cells and serine phosphorylation at 1179 in 
bovine endothelial cells. These kinases include AMP-activated protein kinase, PKC, 
cAMP-dependent protein kinase (PKA) and the serine/threonine kinase Akt, which is 
also known as protein kinase B (PKB). Factors that activate eNOS through PKB/Akt-
mediated phosphorylation of Ser-1177 include estradiol (Haynes et al., 2000), shear 
stress (Dimmeler et al., 1999), VEGF (Dimmeler et al., 2000) and insulin 
(Montagnani et al., 2001). In contrast to the activation that occurs with 
phosphorylation of Ser-1177, phosphorylation of the threonine at position 497 yields 
attenuated eNOS activity (Harris et al., 2001). There seems to be evidence of 
coordinated regulation of eNOS activity by agonists such as VEGF, which cause both 
phosphorylation of Ser-1177 and dephosphorylation of Thr-497 (Michell et al., 2001).  
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Recent work has further demonstrated that PKA signaling leads to eNOS 
phosphorylation at Ser-1179 in bovine endothelial cells and dephosphorylation of 
Thr-497, thereby enhancing enzymatic activity, whereas PKC promotes both the 
dephosphorylation of Ser-1177 and the phosphorylation at Thr-497, resulting in 
attenuated enzyme activity  (Michell et al., 2001). Furthermore, the dephosphorylation 
processes are mediated by phosphatases PP2A and PP1 acting selectively at Ser-1177 
and Thr-497, respectively. Thus eNOS activity is regulated by a complex combination 
of protein-protein interactions and signal transduction cascades involving regulation 
and phosphorylation events (Figure 10). 
Figure 10: Regulation of eNOS enzymatic activity by phosphorylation. A number of protein 
kinases cause activation or inhibition of eNOS indicated by a plus or minus, respectively, by 
phosphorylating Ser1177 or Thr495. Palm = palmitoylation; Myr = myristoylation, CaM = CaM-
binding domain, N = amino terminus, C = carboxyl terminus, P = phosphorylation. (from Michell 
BJ, Curr. Biol. 12, 845-848). 
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Arginine Substrate and NO Production 
 L-arginine is the major substrate of eNOS for NO production. Emerging 
evidence demonstrates that arginase, an enzyme in the urea cycle, competes with 
NOS for the substrate L-arginine and thus reduces NO production as been shown in 
macrophages and vascular endothelial cells (Hallemeesch et al., 2002, Chang et al., 
1998) (Figure 11). This mechanism has been recently implicated in diabetic erectile 
dysfunction, aging-associated endothelial dysfunction, allergen-induced deficiency of 
NO and airway hyperresponsiveness in asthma, pulmonary artery hypertension and 
aortic coarctation-induced hypertensin (Bivalacqua et al., 2001; Berkowitz et al., 
2003; Meurs et al., 2002, Xu et al., 2004; Zhang et al., 2004). Two types of 
mammalian arginase namely arginase I and II encoded by different genes exist 
(Vockley et al., 1996).  
Figure 11: Role of arginase in the modulation of NO production. Arginase hydrolyses L-arginine 
(L-Arg) to L-ornithine and urea; thereby decreasing intracellular availability for NO production. 
Ach = acetylcholine, EC = endothelial cells, SMC = smooth muscle cells,  -  = inhibition. 
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Arginase I, located in the cytoplasm, is expressed most abundantly in the liver, 
while arginase II is a mitochondrial enzyme and is mostly expressed in extrahepatic 
tissues (Jenkinson et al., 1996; Gotoh et al., 1997; Morris et al., 1997). Recent studies 
demonstrate that the activity of arginase could be regulated in many cell types 
including vascular endothelial cells, smooth muscle cells and macrophages by various 
cytokines. 
Depending on cell types studied, activity or gene expression of the two 
isozymes are either constitutively expressed or induced, which regulates NO 
production. In porcine coronary and rat aortic endothelial cells, arginase I is 
constitutively expressed (Zhang et al., 2001; Buga et al., 1996), whereas arginase II is 
induced in response to lipopolysaccharide (Buga et al., 1996).  In human diabetic 
corpus cavernosum, arginase II expression is significantly increased and inhibition of 
this enzyme enhanced NO-dependent relaxation of penile corpus cavernosum smooth 
muscle (Bivalacqua et al., 2001). These observations suggest a potential role of 
arginase II in negative regulation of NO production. However, the exact type of the 
isozymes expressed in human vascular endothelial cells has not yet been elucidated. 
Moreover, the regulatory mechanisms of arginase activity in endothelial cells and in 
atherosclerotic blood vessels are unknown. 
2.4.3.  Reactive Oxygen Species and NO Bioavailability 
The principle source of superoxide anion production in the vascular 
endothelial cells and smooth muscle cells seems to be NAD(P)H oxidases and 
xantine oxidase. NAD(P)H oxidases are expressed in endothelial cells as well as in 
SMC (Griendling et al., 2000; Rajagopalan et al., 1996) and regulated by various 
factors. The activity and expression of subunit p22-phox have been shown to be 
regulated by angiotensin II (Laursen et al., 1997). Studies have shown that in cultured 
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vascular smooth muscle cells angiotensin II markedly increases NADH and NADPH 
oxidase activity (Rajagopalan et al., 1996). Vessels from rats made hypertensive by 
chronic infusion of angiotensin II, produce increased amounts of superoxide, show 
increased NADH/NADPH oxidase activity and have abnormal endothelium-
dependent vasodilation (Ushio-Fukai et al., 1996), which can be improved by 
treatment of the animals with superoxide dismutase (SOD). Under certain conditions, 
NOS may generate superoxide instead of NO, a process called NOS uncoupling (i.e., 
uncoupling of NADPH oxidation and NO synthesis) (Pou et al., 1992). In 
spontaneous hypertension and aging, the production of NO is increased, but 
inefficacious, due to increased inactivation. In salt-induced hypertension NO 
production may be impaired. In atherosclerosis, an enhanced degradation of NO by 
superoxide radicals may explain the reduced endothelium-dependent relaxations. 
Superoxide generation by eNOS is mediated via the heme group of its oxygenase 
domain (Stroes et al., 1998) and is dependent on the presence of its substrate, arginine 
and its cofactor, BHB4B (Vasquez-Vivar et al., 1998; Wever et al., 1997). When there is 
an abundance of both factors, eNOS produces NO. When the concentration of one of 
these factors is relatively low, eNOS generates superoxide. 
Indeed, there are other important sources of superoxide anion generation. In 
human blood vessels, the NAD(P)H oxidase system is the principal source of 
superoxide and is functionally related to clinical risk factors and systemic endothelial 
dysfunction. Furthermore, the C242T polymorphism in the NAD(P)H oxidase 
p22phox subunit is associated with significantly reduced superoxide production in 
patients carrying the 242T allele, suggesting a role for genetic variation in modulating 
vascular superoxide production (Cahilly et al., 2000).  
________________________________________________________________________Introduction 
 35 
In vessels from patients with diabetes mellitus with endothelial dysfunction, 
NAD(P)H oxidase activity and protein subunits are significantly increased compared 
with matched non-diabetic vessels (Endemann et al., 2004). Furthermore, the vascular 
endothelium in diabetic vessels is a net source of superoxide rather than NO 
production, due to dysfunction of endothelial NO synthase (eNOS). This deficit is 
dependent on the eNOS cofactor, BHB4 B, and is in part mediated by protein kinase C 
signalling. These studies suggest an important role for both the NAD(P)H oxidases 
and endothelial NOS in the increased vascular superoxide production and endothelial 
dysfunction in human vascular disease states. As a free radical, NO is inherently 
reactive and mediates cellular toxicity by damaging critical metabolic enzymes and by 
reacting with superoxide to form an even more potent oxidant, peroxynitrite ONOOP- P 
(Zou et al., 2004) (Figure 12).  
 
 
 
 
 
 
 
 
Figure 12: Transportation of the eNOS substrate L-arginine (L-Arg) into the cells and activation 
of eNOS enzyme and interaction of NO with superoxide anion generated from different 
metabolic enzymes which produce peroxynitrite, ONOOP- P.Abbr: BH B4 B= tetrahydrobiopterin, 
SOD=superoxide dysmutase, Fe=ferum, Gs=stimulatory G proteins, CaM=calmodulin, 
CAT=cation transporter, AngII=angiotensin II, PKC=protein kinase C. 
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An increased production of ONOO P-P has been demonstrated in various 
cardiovascular diseases such as diabetes, atherosclerosis, hypertension and aging 
(Sucu et al., 2003; Suarez-Pinzon et al., 2001; Ma et al., 2001; van der Loo et al., 
2000). 
2.5 Anti-thrombotic and Anti-coagulative Effects of Endothelial Cells 
2.5.1. Anti-thrombotic Effects of Endothelial Cells 
The intimal surface of healthy endothelium is both anti-coagulant and anti-
thrombotic. The endothelial cells secrete a variety of molecules important for the 
regulation of blood coagulation and platelet functions. Vessel damage or exposure to 
certain cytokines or proinflammatory stimuli shifts the balance towards a pro-
coagulant/pro-thrombotic phenotype of the endothelial cells. Many of these functions 
of endothelial cells could be attributed to the function of NO (Figure 13). Under 
physiological conditions, unstimulated platelets circulate in blood for approximately 
10 days in a passive manner, but they possess mechanism for recognition of injury 
sites, presence of fissured atheromous plaques, or vessels which have been 
traumatized or severed to which they adhere, spread and undergo activation. Platelets 
release a number of vasoconstrictive factors such as thromboxane AB2B and serotonin 
(5-HT) which possess profound effects both on platelets and vascular wall. Platelets 
also release potent growth factors, such as PDGF stimulating smooth muscle cell 
proliferation and migration leading to neointimal formation. 
Platelets also stimulate NO release from the endothelium by released 
adenosine diphosphate (ADP) and triphosphate (ATP) (Yang et al., 1991). Hence, in 
the healthy arteries with intact endothelium, platelets exhibit endothelium-dependent 
relaxations and inhibition of platelet function at sites where platelets are activated 
(Figure 13, Yang et al., 1991); this tends to flush away and disaggregate evolving 
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platelet clots and thus, preventing the progression of thrombosis and inhibiting 
neointimal formation. In contrast, in blood vessels with injured endothelial cells such 
as after PTCA or in atherosclerotic arteries where NO or PGI B2B production is impaired 
or in the venous bypass grafts where the endothelium releases little amount of NO 
(Lüscher et al., 1988; Yang et al., 1997), platelets evoke only contractions induced by 
platelet-derived serotonin and TxAB2 B on smooth muscle cells, in particular when 
platelets are stimulated by thrombin (Figure 13, Yang et al., 1991, Yang et al., 1994). 
Therefore, thrombin is an important amplifier of platelet-vessel wall interaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Role of the endothelium in modulation of platelet-vessel wall interaction: Under the 
condition of normal endothelial function (left) platelets release adenine nucleotides activating 
purinergic (P) receptors and thrombin activates its receptor on endothelial cells (PAR1) linked to 
the formation of NO. This mechanism leads to vasodilation, inhibition of platelet aggregation and 
inhibition of smooth muscle proliferation/migration in response to the growth factor platelet-
derived growth factor (PDGF) released from activated platelets and thereby plays an important 
protective role to maintain local blood flow and vascular structure integrity. In contrast, under 
the condition of endothelial dysfunction, much less NO is produced and the contractile effects of 
thromboxane A2 (TxA2) and serotonin (5-HT; 5-hydroxytryptamine) released from platelets 
particularly after stimulation by thrombin and smooth muscle proliferation/migration in 
response to PDGF are dominant. ADP=adenosine diphosphate; Tx=TxA2 receptor; S2=5HT2-
serotonergic receptor. O=receptor. α/β = receptor subunits of PDGF. 
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2.5.2. Pro-coagulative Effects of Activated Endothelial Cells: Production of 
Tissue Factor 
In the quiescent state, endothelial cells maintain blood fluidity by promoting 
the activity of numerous anticoagulant pathways, such as the protein C/protein S 
pathway. Activated protein C inactivates two cofactors essential for blood 
coagulation: factors VIIIa and Va. To be effective, protein C must form a complex 
with protein S, which is synthesized by endothelial cells (Stern et al., 1991; Esmon, 
2000). Moreover, the endothelial cell surface is rich in heparin-like 
glycosaminoglycans, providing the main site for inactivation of active thrombin by 
providing a rich source of antithrombin, which is bound to these glycosaminoglycans. 
Endothelial cells also synthesize tissue factor pathway inhibitor (Kato, 2002). Finally, 
receptor-mediated endocytosis of factor Xa by endothelial cells participates to its 
elimination from blood. 
 The endothelium also participates to fibrinolysis by releasing tissue-type 
plasminogen activator (t-PA) and urokinase, allowing the transformation of 
plasminogen into plasmin, which degrades thrombi by digesting fibrin network. 
Unlike extravascular cells, endothelial cells do not normally express the primary 
trigger of the coagulation system, tissue factor. However, when exposed to thrombin, 
cytokines, or LPS, endothelial cells synthesize and express tissue factor at their 
surface (Nawroth et al., 1986; Mackman, 1997).  
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Figure. 14: The coagulation cascade of secondary hemostasis is traditionally divided into three 
parts: the final common pathway, the intrinsic pathway and the extrinsic pathway.  
The coagulation factors are involved in an amplification cascade of proteolytic 
reactions (Figure 14). Small concentrations of initiator substances lead to the 
generation of ever-increasing quantities of the clotting factors lower down the 
cascade, culminating in the formation of thrombin (Schenone, 2004; Norris, 2003). 
Thrombin converts soluble plasma fibrinogen into molecules of fibrin which 
polymerise and form fibrin clot. Fibrin enmeshes the platelet aggregates at the sites of 
vascular injury and stabilises the haemostatic plug. To enable the coagulation 
reactions to proceed, clotting factors need to bind to negatively-charged phospholipid 
surfaces allowing the enzymes and their substrates and cofactors to come into close 
proximity. Disrupted platelet membranes provide the main binding surfaces but 
reactions can also occur on the membranes of red and white cells and damaged blood 
vessel endothelial cells.  
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In short, the coagulation cascade is initiated by FVII which becomes activated 
upon binding to tissue thromboplastin (tissue factor-TF). Activated FVII directly 
activates FX. Activated FX with the aid of FV converts prothrombin to thrombin 
which is generated in insufficient concentrations to convert fibrinogen to fibrin clot. 
Activation of FIX is enhanced by the action of FXI activation of which is one of the 
positive feedback reactions of thrombin. In addition to this effect, thrombin could also 
induce TF expression in endothelial cells (Eto et al., 2002) amplifying the coagulation 
cascade. 
2.5.3. The Role of Tissue Factor (TF) in Cardiovascular Diseases 
In human coronary atherectomy specimens, concentrations of TF antigen and 
activity were found to be higher in plaques taken from patients with de novo angina, 
unstable angina or myocardial infarction as compared to stable patients or patients 
with re-stenosis (Misumi et al., 1998; Annex et al., 1995). In addition, thrombus was 
detected only in TF-positive plaques and fibrin deposition was mainly observed 
around the massive infiltration of TF-positive macrophages in patients with unstable 
angina. These findings suggest a role of TF in the progression to unstable coronary 
syndromes. 
Many studies have investigated the induction of TF-mediated procoagulant 
activity in cultured human endothelial cells, and several stimulating factors have been 
identified including interleukins, tumor necrosis factor-α, endotoxin, and shear stress 
(Haslinger et al., 2003; Mazzolai et al., 2002; Chu et al., 2001). In some studies no or 
only minimal TF activity at the (apical) endothelial cell surface was detected after 
stimulation with tumor necrosis factor. TF expression was more prominently localized 
at the subendothelial matrix, at the basolateral surface, or it remained intracellular in 
the endothelial cells. This suggests a tightly regulated TF expression in endothelial 
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cells which may only gain access to the blood after disruption of the endothelial 
monolayer (Mulder et al., 1994). 
 Some pathways of TF expression described for monocytes–macrophages 
and/or vascular smooth muscle cells, have also been identified in endothelial cells. 
Oxidized low-density lipoprotein is a potent stimulus for TF expression in cultured 
human endothelial cells (Cui et al., 1999; Wang et al., 2000). Ligation of the CD40 
receptor (expression of which might be upregulated after exposure with interferon-
gamma) by T cells or activated platelets increases TF expression on endothelial cells 
(Slupsky et al., 1998). Platelets have also been shown to stimulate TF production in 
human endothelial cells (Becker et al., 2000. Therefore, TF expression in activated 
endothelial cells may importantly contribute to the atherothrombotic events in 
patients with coronary artery disease. 
2.5.4. Regulatory Mechanisms of Endothelial TF Expression 
Intracellular regulatory mechanisms of endothelial TF expression have not 
been completely elucidated. Recent studies have demonstrated that endothelial TF 
expression is positively regulated by the small G-protein, RhoA (Eto et al., 2002; 
Ishibashi et al., 2003) also by the serine/threonine kinase p38PmapkP in different vascular 
cell types (O'Reilly et al., 2003; Eto et al., 2002; McGilvray et al., 2002). Casani et al. 
has demostrated recently that in lipopolysaccharide-stimulated monocytes TF 
expression was blunted partially by the inhibition of the translocation of RhoA to the 
platelet membrane (Casani et al., et al., 2004). There are also demonstrations of a 
reciprocal relationship between procoagulant activity and the PI3K-Akt signaling 
pathway or a negative regulation by Akt (Blum et al., 2001; Kim et al., 2002).  
The small G protein RhoA exerts a wide spectrum of functions including 
regulation of gene expression, cell proliferation, cell migration, cytoskeletal 
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rearrangement, and intracellular vesicle trafficking and protein nucleocytoplasmic 
transportation, acting as a molecular switch (Matozaki et al., 2000), cycle between 
inactive GDP-bound and active GTP-bound forms (Figure 15).  
The exchange of GDP from the inactive form for GTP is on one hand 
stimulated by protein regulators named guanine nucleotide exchange factors (GEFs) 
upon stimulation by various agents or hormones (i.e. growth factors, cytokines, 
integrins and G-protein-coupled receptor ligands). On the other hand, the GDP/GTP 
exchange reaction is inhibited by another type of regulator namely GDP dissociation 
inhibitors (GDI) that prevent GDP dissociation from the GDP-bound form and keep 
the small G protein inactive. 
 Figure 15: General model of regulation of small G-protein activity. Abbr: GDP=guanosine 
diphosphate, GTP=guanosine triphosphate, GDI=GDP-dissociation inhibitor, GAPs=GTPase- 
activating proteins, GEF= Guanine nucleotide exchange factor. 
Multiple downstream effectors of RhoA have been identified. They serve as 
important signal transduction molecules transmitting extracellular signal into the cells 
and regulating multiple cellular functions and also plays a major role in the regulation 
and control of cardiovascular diseases. Activated RhoA, for example associates with 
the membrane where it interacts with the Ser/Thr kinase, Rho-kinase to initiate 
signalling cascades regulating cellular responses. The binding of RhoA.GTP to Rho-
kinase leads, through a conformational change to autophosphorylation and activation 
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of the kinase (Kaibuchi et al., 1999). Activation of Rho-kinase leads to smooth muscle 
contraction, cell migration and cancer metastasis via the regulation of myosin II and 
myosin light chain phosphatase (Somlyo et al., 2000). Many of the vascular protective 
effects of HMG-CoA reductase inhibitors or statins are attributed to inhibition of 
RhoA, which are independent of cholesterol synthesis (Figure 16). Inhibition of 
mevalonate (an important precursor in the biosynthesis of cholesterol) synthesis by 
statins prevents the synthesis of important isoprenoid intermediates such as 
geranylgeranylpyrophosphate (GGPP) which is important in the activation of RhoA 
(Figure 16).  
Figure 16: Inhibition of HMG-CoA reductase by statins has multiple downstream effects, 
including inhibition of cholesterol biosynthesis and of isoprenoid intermediates such as Farnesyl-
pyrophosphate and Geranylgeranyl-pyrophosphate. Geranylgeranylation and farnesylation of 
proteins such as the small GTPases RhoA, Rac and Ras are important for activation of the 
signalling molecules. Abbr: PP= pyrophosphate. 
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2.6 High-Density Lipoprotein (HDL) and Cardiovascular Protection 
2.6.1. Epidemiological Evidence for the Protective Effects of HDL 
Prospective epidemiological studies have consistently demonstrated that 
plasma HDL cholesterol concentration is inversely related to the incidence of 
coronary artery disease (CAD). The Framingham Heart Study reveals that HDL-C 
levels are a strong, graded and independent cardiovascular risk factor. The protective 
effects of an elevated HDL-C level persist until age 80 years (Gordon et al., 1977). 
Conversely, a low HDL-C level is associated with increased CAD risk even with 
"normal" (<5.2 mmol/L) total plasma cholesterol levels.  
Coronary disease risk is increased by 2% in men and 3% in women for every 1 
mg/dL (0.026 mM) reduction in HDL cholesterol, and in the majority of studies, this 
relationship remains statistically significant after adjustment for other lipid and non-
lipid risk factors (Maron DJ, 2000). The ability of HDL-cholesterol to predict CAD 
independently of LDL-cholesterol is exemplified by data from the Prospective 
Cardiovascular Münster (PROCAM) study, where incidence of CAD rises in relation 
to both decreasing HDL levels, as well as increasing LDL levels (Assmann et al., 
1992). Incidence of myocardial infarction in 10 years is reported to be significantly 
higher according to baseline triglyceride level and low-density lipoprotein cholesterol 
(LDL-C) level in patients with a low high-density lipoprotein cholesterol (HDL-C) 
level (<45 mg/dL) in the PROCAM study (Figure 17). Therefore, low levels of HDL 
(<0.9 mmol/l) have specifically been related to an increase in coronary mortality, 
particularly in diabetic subjects, and increased risk of death due to CAD, whether total 
cholesterol concentration is below or above 5.2 mmol/l. Despite the strong 
epidemiological link between reduced HDL levels and the incidence of CAD, it is 
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unclear whether HDL plays a direct or indirect role in the pathogenesis of 
atherosclerosis.  
Figure 17: Incidence of myocardial infarction (MI) in 10 years according to baseline triglyceride 
level and low-density lipoprotein cholesterol (LDL-C) level in patients with a low high-density 
lipoprotein cholesterol (HDL-C) level (<45 mg/dL) in the Prospective Cardiovascular Münster 
study. There were 206 coronary events in 2,490 men aged 35 to 65 years (Assmann G; Am J 
Cardiol. 2001). 
2.6.2. Cardiovascular Protective Effects of HDL 
The cardioprotective effects of HDL are attributed mainly to the two 
categories of functions that are the reverse cholesterol transport and cholesterol-
independent effects (Figure 18). 
 
 
 
 
 
 
 
Figure 18: General mechanisms of HDL on vascular function. 
Atheroprotective Role of HDL 
• eNOS activation
• Inhibition of platelet aggregation
• Anti-coagulative and profibrinolytic effects
• Anti-inflammatory and Anti-oxidative
• Reverse cholesterol transport
• Cholesterol-independent effects
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Cholesterol-lowering Effect: The Reverse Cholesterol Pathway (RCT) 
The metabolism of HDL involves sophisticated dynamics in its own pathway 
as well as balances with other lipoproteins. RCT appears to be the primary mechanism 
by which excess peripheral cholesterol is delivered back to the liver for disposal as 
bile salts or biliary cholesterol and to steroidogenic organs for the conversion into 
steroid hormones. 
The RCT pathway regulates the formation, conversion, transformation, and 
degradation of HDL (Rader et al., 2003) (Figure 19). Excess cholesterol in the 
macrophages results in the upregulation of the ATP-binding cassette A1 (ABCA-1) 
transporter, which picks up the free cholesterol and phospholipids within the cells and 
transports them to cell surface. The hepatically secreted apoA-I becomes associated 
with phospholipids and forms the discoidal pre- HDL, the nascent form of HDL in 
plasma. This form of HDL, also termed lipid-poor ApoA-1, is involved in the removal 
of cholesterol and phospholipids from the peripheral tissues.  
 Inadequately lipidated ApoA-1 and nascent HDL are rapidly catabolized and 
cleared from serum, resulting in hypoalphalipoproteinemia. Cellular exposure to 
ApoA-1 increases the delivery of vesicles enriched with cholesterol from the Golgi 
apparatus to the plasma membrane, resulting in increased cholesterol efflux. 
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Figure 19: The reverse cholesterol transport contributes to atheroprotective effects of HDL. 
Abbr: CM = Chylomicron, LPL = lipoprotein lipase, CMR = chylomicron remnant, LDLR = 
LDL receptor, LRP = LDL related protein, SR-B1 = scavenger receptor class B type 1, SR A = 
scavenger receptor A, HL = hepatic lipase, PLTP = phospholipid transfer protein, CETP = 
cholesterol ester transfer protein, IDL = intermediate density lipoprotein, ABCA1/G1 = ATP-
binding cassette A1/G1 transporter, Apo A1 = apolipoprotein A1. 
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Free cholesterol on the surface of HDL is esterified by the activity of lecithin: 
cholesterol acyltransferace (LCAT), forming larger HDL particles. Lipid-free apo A-I 
or lipid-poor pre–ß-HDL particles produced in the intestine or liver or shed during 
lipolysis of triglyceride-rich lipoproteins initiate efflux of phospholipids and 
cholesterol from cell membranes in a process facilitated by phospholipids transfer 
protein (PLTP).  
The HDL particles finally transfer cholesterol to the liver by at least two 
distinct processes (Figure 19): through an exchange of cholesteryl ester for 
triglycerides in an interaction with triglyceride-rich lipoproteins, mediated by 
cholesteryl ester transfer protein (CETP) or through docking to the scavenger receptor 
Class B type 1 (SR-B1), expressed on the hepatocyte cell membrane. Cholesteryl 
esters readily move to the core of HDL particles, producing a steady gradient of free 
cholesterol and enabling HDL to accept cholesterol from various donors. The 
reciprocal exchange of cholesteryl ester for triglycerides mediated by CETP moves 
the bulk of the cholesteryl esters to lipoprotein remnant particles, which are 
subsequently cleared by the liver.  
At the same time, HDL becomes enriched with triglycerides, which are 
substrates for hepatic lipase (HL). The concerted action of CETP-mediated 
cholesteryl ester transfer and HL-mediated hydrolysis of triglycerides and 
phospholipids helps to form the smaller HDL particles that are the preferred binding 
partners for SR-B1, the major HDL receptor on hepatocytes. The binding of HDL 
with SR-B1 mediates the selective uptake of cholesteryl esters that have not 
undergone CETP-mediated transfer to apo B–containing particles (intermediate-
density lipoprotein [IDL] and low-density lipoprotein [LDL]). These Apo B 
containing particles are also taken up by peripheral tissues such as fat or muscles by 
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the action of lipoprotein lipase (LPL). Finally, by hydrolyzing triglyceride and 
phospholipids, HL regenerates smaller HDL and lipid-free ApoA-I, which in turn are 
rapidly reloaded with cellular cholesterol and phospholipids to form new HDL 
particles. 
Cholesterol Independent Effects 
As shown in Figure 18, the pleiotropic effects or cholesterol independent 
effects of HDL on protection of vascular function have been explored in recent years. 
Much interest has been focused on the endothelial function in the most recent years. 
HDL exerts multiple biological actions on the vascular endothelium. Incubation of 
cultured endothelial cells with HDL activates eNOS in a process that involves the 
binding of ApoA-I to the SR-BI (Yuhanna et al., 2001). The mechanism by which 
HDL activates eNOS is not clear.  
As mentioned previously, the enzymatic activity of eNOS is regulated by a 
variety of mechanisms, including membrane localization, intracellular calcium and 
ceramide, and phosphorylation (Shaul et al., 2002). On one hand, HDL interaction 
with SR-BI modifies membrane cholesterol distribution and morphology, thus 
potentially influencing eNOS activity. This same interaction leads to an intricate 
activation of kinases (tyrosine kinase, PI3K, Akt and mitogen-activated protein 
kinase, MAPK) cascades and ultimately resulting in eNOS phosphorylation and 
activation (Figure 20) (Li et al., 2002; Mineo et al., 2003. HDL also enhances eNOS 
expression in cultured human endothelial cells (Kuvin et al., 2002). 
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Figure 20: Model of HDL-induced eNOS activation and vasodilation by the lysophospholipid 
receptor S1P3. Abbr: SR-B1=scavenger receptor class B type 1; A-1=ApoA-1; 
SPC=Sphingosylphosphorylcholine; S1P=Sphingosine-1-phosphate; LSF=Lysosulfatide; PI-
PLC=phosphatidylinositol-specific phospholipase C; NO=Nitric oxide; G=G-proteins; S1PB3 B= 
lysophospholipid receptor; N and C, amino- and caboxy-terminus of SR-BI. (Nofer JR et al.  
2003). 
In vivo studies provide additional support to the concept that HDL prevents 
endothelial dysfunction by promoting endothelial NO production. Early investigations 
by quantitative coronary angiography and intravascular ultrasound analysis showed a 
positive correlation between plasma HDL concentration and NO-dependent coronary 
vasodilation. A short-term treatment with niacin in patients with low HDL causes an 
elevation of plasma HDL with a parallel increase of NO-mediated vasodilation. Even 
more striking, the intravenous infusion of reconstituted HDL (rHDL) in 
hypercholesterolemic subjects rapidly restores the altered endothelium-dependent 
vasodilation by increasing NO bioavailability. (Spieker et al., 2002; Bisoendial et al., 
2003) Direct inhibition of platelet aggregation by HDL or rHDL has also been shown 
(Aviram et al., 1983; Nofer et al., 1998; Higashihara et al., 1991). HDL has been 
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known to inhibit activation of coagulation factor X by factor VIIa and TF purified 
from placenta (Carson et al., 1981). These studies suggest a modulatory role of HDL 
or rHDL in hemostasis. HDL was also reported to enhance the anticoagulant activity 
of activated protein C and protein S. The observation that the infusion of rHDL into 
human volunteers limits the procoagulant state associated with endotoxemia supports 
the concept that HDL may exert a significant anticoagulant effect in vivo in humans. 
Other pleiotropic effects of HDL such as anti-inflammatory and anti-oxidative effects 
(Figure 18) have also been reported. 
2.7 Aims of the Thesis 
The thesis aims to investigate  
(1) the potential role of RhoA/ROCK pathway in the regulation of eNOS gene 
expression and enzymatic activity and the underlying mechanism  
(2) the role of RhoA/ROCK in endothelial TF expression  
(3) the effects of HDL on eNOS activation and TF expression and the 
underlying mechanisms.    
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II. MATERIAL AND METHODS 
1. Materials 
Thrombin was from Calbiochem; L-α-phosphatidyl-L-serine, L-α-
phosphatidylinositol 4,5-diphosphate sodium salt and platelet derived growth factor-
BB (PDGF-BB) from Sigma; Redivue [γ- P32P ]ATP and L-[U- P14 PC] arginine 
monohydrochloride from Amersham; Thin-layer-chromatography (TLC) plates 
(silica-60, WF B2545 B) from Merck; endothelial cell growth supplement (ECGS) from 
PromoCell GmbH; anti-eNOS monoclonal antibody from BD Transduction 
Laboratory company; anti-human tissue factor from American Diagnostica, anti-
RhoA monoclonal antibody, protein A/G PLUS-agarose and Glutathione-agarose 
from Santa Cruz Biotechnology, Inc.; anti-p38Pmapk P, anti-phospho- p38 Pmapk P , anti-
phospho-GSK3, anti-Akt, anti-Phospho-Akt (Ser473 and Thr308) antibodies, anti-
phospho-eNOS (Ser1177) antibody and Akt kinase assay kit from Cell Signaling 
Technology; anti-phosphotyrosine (4G10) agarose conjugate from Upstate 
Biotechnology; Anti-mouse and anti-rabbit IgG (H+L) alkaline phosphatase (AP) 
conjugate and Western BlueTM stabilized substrate for AP from Promega. The 
recombinant glutathione S-transferase (GST)-TRBD (Rhotekin Rho binding domain 
7-89 amino acid) fusion protein was purified (Ming et al., 1998). All the cell culture 
materials were purchased from Gibco. Fluvastatin was provided by Novartis (Basel, 
Switzerland); anti-RhoA monoclonal antibody from Santa Cruz Biotechnology, Inc. 
(Nunningen, Switzerland); anti-arginase I antibody from BD Transduction 
Laboratory; anti-arginase II rabbit polyclonal antibody was generated by Eurogentech, 
S.A, by immunization with a synthesized peptide containing the 16 C-terminal amino 
acid (AA 339 –354) of human arginase II; anti-α-tubulin antibody from Sigma; anti-
mouse and – rabbit IgG alkaline phosphatase (AP) conjugate were purchased from 
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Promega (Wallisellen, Switzerland); BCIP/NBT solution was purchased from Upstate 
Biotechnology Inc. (Lucerne, Switzerland). Endothelial cell growth supplement 
(ECGS) pack from PromoCell GmbH (Allschwill, Switzerland); all cell culture media 
and materials were purchased from Gibco BRL (Basel, Switzerland). 
2. Animals and Organ Chamber 
13 male apolipoprotein E-deficient (ApoEP-/-P) mice and 13 male C57BL/6J wild 
type control mice (4-weeks-old) were obtained from Jackson Laboratory (USA). To 
accelerate lesion formation, animals were fed a Western type diet (Harlan TD88137, 
21.2% total fat and 0.2% cholesterol) for 4 months (Barton M et al., 1998) At 5 
months of age, animals were anesthetized with 7 pentobarbital (100 mg/kg i.p.), the 
entire aorta from the heart to the iliac bifurcation were removed, placed into cold 
(4°C) Krebs bicarbonate solution, dissected free from fat and adhering perivascular 
tissue. The isolated aorta was cut into parts as required for different analyses for 
protein expression by Western blot. The isolated vessel was snap-frozen in liquid 
nitrogen. The tissues were homogenized and sonicated in arginase lysis buffer for 
arginase activity assay or in extraction buffer for analysis of protein expression by 
Western blot (Ming et al., 2002). Protein concentration was determined by Bradford 
method (Bio-Rad). Animal handling and experimentation were approved by local 
animal ethical committee. 
3. Vascular reactivity studies 
The isolated descending thoracic aortas with intact endothelium from wild 
type and ApoEP-/-P mice were cut into rings (3 mm in length) which were suspended in a 
Multi-Myograph System (Model 610M, Danish Myo Technology A/S, Denmark) 
(Viswambharan et al., 2003). To study the role of arginase in modulation of eNOS 
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function, aortic rings with endothelium in parallel were incubated with or without the 
arginase inhibitor L-norvaline (20 mmol/L) for 1 hour (Chang et al., 1998, Wu et al., 
1998, Zhang et al., 2001, Bivalacqua et al., 2001, Berkowitz et al., 2003) and then 
contracted with norepinephrine (0.3 µmol/L). L-arginine (I mmol/L) was added on top 
of the contraction. 
4. Cultivation of Human Umbilical Vein Endothelial Cells (HUVECs) 
Endothelial cells were isolated from human umbilical veins {Eto et al., 2001). 
Fresh blood vessels were harvested in cold sterile phosphate-buffered saline (PBS) 
with antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin). The vessels were 
incubated with collagenase type II 75 U/ml for 20 minutes in PBS. Cell pellets were 
then collected by centrifugation, seeded in culture dishes coated with 1% gelatin and 
cultured in RPMI 1640 supplemented with 20 mmol/L L-glutamine, HEPES buffer 
solution, 100 U/ml penicillin and 100 µg/ml streptomycin, 50 µg/ml ECGS, 25 µg/ml 
heparin and 5% fetal calf serum (FCS). Endothelial cells are characterized by the 
typical cobblestone and non-overlapping appearance and in-direct 
immunofluorescence staining using specific antibodies against von Willebrand factor. 
Human smooth muscle cells (hSMCs) were isolated from human saphenous veins 
(Yang et al., 1998). 
5. Measurement of arginase activity 
Arginase activity in the cells and aortic tissue lysates was measured by 
colorimetric determination of urea formed from L-arginine (Chang et al., 2000). To 
prepare cell lysate for arginase assay, cells were first rinsed with ice-cold Dulbecco’s 
PBS twice after each specified treatment and then scraped into 300 µl of lysis buffer 
containing 50 mM Tris-HCl (pH 7.5), 0.1 mM EDTA, 0.1 mM EGTA, 1 µg/ml 
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leupeptin, 1 µg/ml aprotinin, and 0.1 mM PMSF. Cells were lysed by sonication at 20 
kHz (B.Braun Labsonic Model 1510, Melsungen, Switzerland) for 30 s (10 s/cycle). 
Arginase activity in the cell lysates was measured. The cell lysate (50 µl) was added 
to 50 µl of Tris-HCl (50 mM; pH 7.5) containing 10 mM MnCl B2 B. Macrophage 
arginase was then activated by heating this mixture at 55–60°C for 10 min. The 
hydrolysis reaction of L-arginine by arginase was conducted by incubating the 
mixture containing activated arginase with 50 µl of L-arginine (0.5 M; pH 9.7) at 
37°C for 1 h and was stopped by adding 400 µl of the acid solution mixture 
(HB2 BSOB4 B:HB3 BPOB4 B:HB2 BO=1:3:7). For colorimetric determination of urea -
isonitrosopropiophenone (25 µl, 9% in absolute ethanol) was added, and the mixture 
was heated at 100°C for 45 min. After placing the sample in the dark for 10 min at 
room temperature, the urea concentration was determined spectrophotometrically by 
the absorbance at 550 nm measured with a microplate reader (BioRad Microplate 
Reader Model 680). The amount of the urea produced was used as an index for 
arginase activity. 
6. Generation of recombinant adenoviruses (rAd) expressing different 
mutants. 
Recombinant Adenovirus expressing PI3K and PKB mutants 
Expression plasmid encoding an active PI3K mutant (pEF-BOS-rCD2-p110) was 
obtained from DA Cantrell (Imperial Cancer Research Fund, London, UK). The 
active PI3K mutant (rCD2-p110) is a chimeric molecule in which the cytoplasmic 
domain of the rat CD2 (rCD2) cell-surface antigen was replaced with the catalytic 
subunit of PI3K, p110α. This targets PI3K catalytic subunit at the membrane and 
thereby confers PI3K constitutively active (Figure 21). Cell surface expression of the 
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rCD2-p110 was confirmed by flow cytometric immunofluorescenc analysis with an 
anti-rCD2 monoclonal antibody (Reif et al., 1996).  
Figure 21: Schematic representation of the active mutant of PI3K employed. 
pCMV constructs encoding a hemagglutinin (HA) epitope-tagged membrane-targetted 
active PKB (pCMV-m/p-HA-PKBα) and an inactive PKB (pCMV-HA-PKB-α-
K179A) were from Dr. B. Hemmings (Andjelkovic et al., 1997) (Figure 22).  
Figure 22: Schematic representation of Akt mutants employed. PH, pleckstrin homology domain. 
All the PKB constructs are HA epitope tagged at the N-terminus.  
The active mutant of Akt was achieved by membrane localization of the mutant 
by attaching a myristoylation/palmitoylation signal at the N-terminal via its PH 
domain, since both of these modifications have been shown to be sufficient to localize 
many cytosolic proteins to the plasma membrane. Membrane-targeted PKB is 
constitutively active by an increased phosphorylation at Thr P308P and Ser P473P. The kinase-
deficient mutant is made inactive by a point mutation in its ATP-binding site (lysine 
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at 179 to alanine). In this mutant the level of phosphorylation for SerP473 Pwas much 
lower. Membrane attachment of the mutants was confirmed by subcellular 
localization of proteins expressed in 293 cells by immunofluorescence using the anti-
hemagglutanin (anti-HA) antibody (Andjelkovic et al., 1997).  
The generation of recombinant adenovirus expressing rCD2-p110 or PKB mutants 
driven by the cytomegalovirus (CMV) promoter was carried out through homologous 
recombination between co-transformed adenoviral backbone virusmid 
(VmAdcDNA3, ∆E1∆E3) and the corresponding adenoviral transfer plasmid  
(pcDNA3.1 from Invitrogen) in E.coli (Heider et al., 2000).  
The rCD2-p110 and PKB mutants cDNA were first subcloned into the adenoviral 
transfer plasmid pcDNA3.1 (Figure 23) allowing the insertion of the transgene into 
the E1 region of a cloned ∆E1∆E3 adenoviral backbone (vmAdcDNA3) bearing an 
empty expression cassette homologous to the one of the pcDNA3.1.  
Figure 23: Subcloning ofThe rCD2-p110 and PKB mutant cDNA were subcloned into adenoviral 
transfer plasmids. Abbr: T7 Prom=T7 promoter. 
The transfer plasmid pcDNA3.1-rCD2-p110 was then digested with SalI, and co-
transformed with SwaI-linearised vmAdcDNA3 into a recombinant proficient E.coli 
strain (BJ5183) by electroporation to allow homologous recombination in BJ5183. 
The plasmid pcDNA3.1-m/p-HA-PKBα and pcDNA3.1-HA-PKBα-K179A were 
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digested with StuI and SspI, and co-transformed with SwaI-linearised vmAdcDNA3 
into BJ5183 (Figure 24). 
 Figure 24: Generation of recombinant adenovirus expressing PI3K and PKB mutants by 
homologous recombination in a recombinant proficient E.coli strain BJ5183. Abbr: CMV=CMV 
promoter. 
The candidate recombinants were subsequently screened by colony PCR using 
primer UAd and LrAd (Figure 25).  
UAd sequence:        5’- GCCCAGGTGTTTTTCTCAGTG -3’                        
LrAd sequence:    5’- ATGGGGTGGAGACTTGGAAATC -3’ 
Figure 25: Candidate recombinant adenoviruses were screened by colony PCR using primer pair 
UAd and LrAd. Product size (opt. TBHB: 57°C, 2mM MgClB2B): 488bp. 
The positive clones were then re-transformed into another E.coli strain HB101 
allowing higher plasmid yield. The resultant recombinant virusmids were digested 
with PacI and transfected into E1-complementing packaging cells (HER911) to 
generate recombinant adenovirus. The primary crude lysates of the recombinant 
VmAdcDNA3
∆E1 ∆E3 34.7kb
Adenoviralbackbone)
UAd
Pac1
AdITR
CMV
Swa1
BGHpA
+f1 (partial)
AdenoH5dl324
backbone
∆E3
Pac1
pcDNA3.1
(transfer plasmid)
LrAd
Sal1
CMV
BGHpA f1ori
Sal1
rCD2-p110
HA-PKBα
ppolyII
Sal1
CMV
BGHpA f1ori
Sal1
Ori AmpR
rAd-rCD2-p110
rAd-PKB
UAd
Pac1
AdITR
CMV
Swa1
BGHpA
+f1 (partial)
AdenoH5dl324
backbone
∆E3
Pac1
Pac1
AdITR
CMV
Swa1
BGHpA
+f1 (partial)
AdenoH5dl324
backbone
∆E3
Pac1
rAd-rCD2-p110
rAd-PKB
LrAd
______________________________________________________________Materials and Methods 
 59 
adenoviruses were prepared as viral stocks and used to infect HER911 cells for scale 
up of the viral preparation. The viral titer was determined by plaque assay. 
Recombinant Adenovirus expressing Rho and ROCK mutants 
Expression plasmid encoding an active RhoA (pcDNA3.1-Rho63L) and a 
dominant negative RhoA (pcDNA3.1-Rho19N) were obtained from Dr Joseph J. 
Baldassare (Hu et al., 1999) (Figure 26). Mammalian expression vector, pEF-BOS 
constructs encoding a myc-tagged constitutively active ROCK (pEF-BOS-myc-CAT) 
and a dominant negative form of ROCK (pEF-BOS-myc-RB/PH (TT)) were from Dr. 
K.Kaibuchi (Amano et al., 1998).  
Figure 26: Schematic representation of RhoA and ROCK mutants employed. Abbr: KD=kinase 
domain, RBD=Rho binding domain, PH=Pleckstrin homology domain, d.n.=dominant negative, 
wt=wild type, CAT=catalytic. 
The active mutant of RhoA was made constitutively active by glutamine-to-
leucine substitution at position 63, leading to structural modification of RhoA. This 
modification lacks an amide group due to leusine substitution. Lack of amide group at 
position 63 of Rho (mimicking deamination) inhibits both intrinsic GTP hydrolysis 
and impairs RhoGAP-mediated GTP hydrolysis (abolishing GTPase activity), thus 
keeping it in the active form. N19RhoA acts as a dominant negative mutant due to its 
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decreased binding affinity to GTP and an increased affinity to RhoGEFs, thus acting 
as a competetive inhibitor of the endogenous Rho (Schmidt et al,. 1997). 
Rho-kinase is composed of NHB2 B-terminal catalytic coiled-coil, the inhibitory 
COOH-terminal portion consisting of Rho-binding (RB) and PH domains. In the 
resting state, the C-terminal domain interacts with the catalytic domain to maintain it 
inactive. Upon stimulation, the active form of Rho interacts with the RB domain, 
alters the conformation of ROCK and thereby, relieves the inhibition by the RB and 
PH domains. The active mutant of ROCK was made by deletion of the inhibitory 
COOH-terminal portion. This renders the NHB2 B-terminal catalytic domain as 
consitutively active. The dominant negative mutant of ROCK contains only C-
terminal portion consisting of the RB and PH domains, in which point mutations 
(Asn-1027 and Lys-1028 to Thr) were introduced to abolish the Rho-binding activity 
and thereby constitutively inhibit ROCK activity (Amano et al., 1999).   
Generation of recombinant adenovirus expressing HA-tagged RhoA and 
ROCK mutants driven by the cytomegalovirus (CMV) promoter was carried out 
through homologous recombination between co-transformed virusmid (VmRL-
CMV1) and the corresponding adenoviral transfer plasmid (pSTCO-HA.mcs) in E. 
coli (Heider et al., 2000).  
The Rho and ROCK mutants cDNAs were first subcloned into the adenoviral 
transfer vector pSTCO-HA.mcs allowing the insertion of the transgene into the E1 
region of a cloned ∆E1∆E3 adenoviral backbone (vmRL-CMV1 or vmAdcDNA3, 
respectively) bearing an empty expression cassette homologous to the one of the 
pSTCO-HA.mcs (Figure 27).  
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Figure 27: The Rho and ROCK mutants cDNAs were first subcloned into the adenoviral transfer 
vector pSTCO-HA. 
The transfer plasmid pSTCO-HA-Rho63L, -Rho19N, -CAT and -RB/PH (TT) 
was then digested with AclI and XhoI, and co-transformed with SwaI-linearized 
vmRL-CMV1 into a recombination proficient E.coli strain (BJ5183) by 
electroporation to allow homologous recombination in BJ5183 (Figure 28).  
Figure 28: Expression vector pSCT1 and adenoviral backbone recipient vector Vm-CMV1. 
Generation of recombinant adenovirus expressing RhoA and ROCK mutants by homologous 
recombination in a recombinant proficient E.coli strain BJ5183. Abbr: CMV=CMV promoter, 
T7=T7 promoter. 
The candidate recombinants were subsequently screened by colony PCR using 
primers UAd and LrAd (Figure 29). The positive clones were re-transformed into 
another strain HB101 allowing higher plasmid yield. The resultant recombinant 
virusmids were digested with PacI and transfected into E1-complementing packaging 
cells (HER911) to generate recombinant adenovirus. The primary crude lysates of the 
recombinant adenoviruses were prepared as viral stocks and used to infect HER911 
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cells for scale-up of the viral preparation. The viral titer was determined by plaque 
assay. The control recombinant adenovirus expressing HA-tagged LacZ and GFP 
(rAd-HA-LacZ and rAd-GFP) was also prepared (Heider et al., 2000). 
Figure 29: Resultant recombinant adenoviruses were screened by colony PCR. 
Plaque assay  
Plaque assay was carried out as follows: Recombinant virus was diluted in 
DMEM containing 2% FCS in 10-fold serial dilution ranging from 10P-4 P to 10 P-9 P. 
Diluted viral preparations were infected in duplicates to HEK293 cells cultured in 6-
well plates and incubated with the same medium for 16 hours. Medium containing the 
virus was then aspirated and the cells were overlayed with 2 ml of agar overlay 
solution (0.2% agar in DMEM/2% FCS) per well. The agar was allowed to solidify at 
room temperature for 30 minutes and the plates were then returned to the incubator. 
Four days following the initial overlay another 2ml of agar overlay solution was 
added to the each well and incubated further till the 9Pth P day. Plaques were counted 
under a light microscope in each well. The titre of the adenoviral stock was expressed 
as plaque forming units/ml (pfu/ml). 
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7. Adenoviral infection.  
HUVECs were maintained in complete RPMI-1640 supplemented with 5% 
FCS and ECGS at 37°C in an atmosphere of 5% CO B2 B and were passaged when they 
reached confluence. Cells were seeded at a density of 2 x 10P5P / 6 cm dish in complete 
RPMI-1640 supplemented with 5% FCS and ECGS. Two days later, cells were 
infected with the recombinant adenovirus at titers ranging from 100 to 150 MOI and 
further incubated in 0.2% FCS RPMI-1640 supplemented with ECGS for 18 hours or 
48 hours before treatment and extraction. 
8. Western blot (WB) 
Cell extracts were prepared by lysing cells in extraction buffer: 120 mM NaCl, 
50 mM Tris, pH 8.0, 20 mM NaF, 1 mM benzamidine, 1 mM EDTA, 1 mM EGTA, 1 
mM sodium pyrophosphate, 30 mM 4-nitrophenyl phosphate disodium salt 
hexahydrate, 1% NP-40 and 0.1 M PMSF (Ming et al., 1994). 40 µg extracts were 
subjected to SDS-PAGE and electrophoretically transferred to an Immobilon-P 
membrane (Millipore), and the resultant membrane was incubated overnight with the 
corresponding first antibody at 4°C with gentle agitation after blocking with 5% 
skimmed milk. The protein was decorated with a corresponding anti-mouse or anti-
rabbit AP-conjugated secondary antibody and detected using Western BlueTM 
stabilized substrate. Quantification of the signals was performed using NIH Image 
1.62 software. In all the plotted graphics, each point represents the average value from 
three to eight independent experiments. 
9. PKB/Akt kinase assay 
PKB/Akt kinase activity was analysed by non-radioactive 
immunoprecipitation-kinase assay using the Akt kinase assay kit from Cell Signaling 
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Technology. 30 µg cell extracts (200 µl) were incubated 2 hours with immobilized 
Akt 1G1 monoclonal antibody. After extensive washing the kinase reaction was 
performed at 30°C for 30 min in the presence of 200 µM cold ATP and GSK-3 
substrate. Phosphorylation of GSK-3 was measured by western blot using phospho-
GSK-3α/β (Ser21/9) antibody. 
10. PI3-Kinase activity assay 
Cell extracts were prepared by lysing cells on ice for 15 min by the addition of 
250 µl of lysis buffer containing 20 mM Tris.HCl, 138 mM NaCl, 2.7 mM KCl, pH 
8.0 supplemented with 5% glycerol, 1 mM MgCl B2 B, 1 mM CaCl B2 B, 1 mM sodium-o-
vanadate, 20 µM leupeptin, 18 µM pepstatin, 1% NP-40, 5 mM EDTA and 20 mM 
NaF. Cell debris and nuclei were removed by centrifugation at 10,000 x g for 10 min 
at 4°C, and 40 µg of the cell lysate was then immunoprecipitated with 2 µl of anti-
PI3-K p85 antibody and protein A/G PLUS-agarose for 4 h at 4°C. The agarose beads 
containing the anti-PI3-K p85 immune complexes were washed twice with wash 
buffer (0.1 M Tris-HCl, pH 7.4 / 0.5 M LiCl) and twice with kinase buffer (20 mM 
HEPES, pH 7.4 / 5 mM MgClB2 B), and then resuspended in 60 µl of kinase buffer 
containing 10 µCi of [γ- P32P ]ATP, 60 µM ATP and 10 µg each of phosphatidylserine 
(PS) and phosphatidylinositol (PI). The kinase reaction was allowed to continue for 
10 min at 30°C. The reaction was then stopped by addition of 200 µl of 1N HCl. The 
lipid reaction products were extracted with 400 µl CHB3 BCl/Methanol (1:1) and dried, 
and then resuspended in 40 µl of spotting solution (CHB3 BCl/Methanol 2:1) and 
analysed on TLC silical gel plate by using CHB3 BCl/Methanol/HB2 BO/NHB4 BOH 
(45:35:8.5:1.5 v/v) as the separation solvent. The product of PI3P was quantified with 
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a phosphorImager densitometry (Bio-Rad) by using ImageQuant software Quantity 
One (Bio-Rad). 
11. Measurement of eNOS activity (L-Citrulline assay) 
eNOS activity was measured by L-citrulline assay (Heller et al., 1999). 
Adenovirus-infected semi-confluent HUVECs were incubated at 37°C for 30 minutes 
in HEPES buffer pH 7.4 (in mM): 10 HEPES, 145 NaCl, 5 KCl, 1 MgSOB4 B, 10 
glucose, 1.5 CaCl B2 B containing 0.25% BSA. 0.5 µCi/ml L-[P14 PC] arginine was added to 
each dish for one hour before the reaction was stopped with cold phosphate-buffered 
saline (PBS) containing 5mM L-arginine and 4mM EDTA. The cells were then 
denatured in 96% ethanol. After evaporation the soluble cellular components were 
dissolved in 20mM HEPES-Na (pH 5.5) and applied to well-equilibrated DOWEX 
(Na P+P form) column. The pellets were dissolved in western blot extraction buffer for 
protein concentration determination. The [P14 PC]-citrulline content of the eluate was 
quantified by liquid scintillation counting. Citrulline production by the different 
infections was expressed in pmol/µg cellular protein obtained after subtracting the 
basal citrulline release. The basal release was determined from the L-Nitro-arginine 
methyl ester (L-NAME) 100mM, 30min pre-incubation-inhibitable radioactivity in 
non-infected cells. 
12. Pull-down assay of GTP-RhoA 
The activation of RhoA was assessed by a pull-down assay (Ren et al., 1999). 
HUVECs were washed with ice-cold Tris-buffered saline and lysed in RIPA buffer 
(50 mM Tris, pH 7.2, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 500 
mM NaCl, 10 mM MgCl B2 B, 10 µg/ml each of leupeptin and aprotinin, and 1 mM 
PMSF). 200 µg of cell lysates were incubated with 10 µg GST-TRBD beads at 4°C 
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for 60 min. The beads were washed four times with buffer B (Tris buffer containing 
1% Triton X-100, 150 mM NaCl, 10 mM MgCl B2 B, 10 µg/ml each of leupeptin and 
aprotinin, and 0.1 mM PMSF). Bound Rho proteins were then detected by Western 
blot using a monoclonal antibody against RhoA (Santa Cruz Biotechnology). The 
total amount of RhoA in cell lysates was used as a control for the cross-comparison of 
Rho activity (level of GTP-bound Rho). 
13. Statistics  
In all experiments ‘n’ equals the number of experiments or animals. 
Relaxations to stimulus are expressed as percentage of decrease in tension of the 
precontraction to norepinephrine (10P-7 PM). All data is expressed as mean ± SEM. 
Statistical analysis was performed with unpaired t test or ANOVA with Bonferroni’s 
post-test. Differences in mean values at p<0.005 is considered to be siginificant in all 
experiments in the study. 
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III. RESULTS  
 
Part 1: RhoA/ROCK Suppresses eNOS Gene Expression and Enzyme Activation 
via Inhibition of Phosphorylation. 
The Rho family of GTPases plays important roles in regulating a diverse set 
of biological activities (Aspenstrom et al., 1999, Seasholtz et al., 1999). The role of 
RhoA in the regulation of vascular functions has been gaining increasing attention in 
cardiovascular research (Fukata et al., 2001, Laufs et al., 2000). Decreased 
bioavailability of endothelium-derived NO is a common feature of several 
cardiovascular disorders (Wever et al., 1998). Studies with statins which indirectly 
inhibits RhoA have been shown to increase NO production, at least partly by 
regulation of eNOS gene expression (Hernandez-Perera et al., 1998). However, statins 
have also been shown to activate protein kinase B (PKB) which is a direct upstream 
effector of eNOS. These results prompted us to hypothesize that a cross-talk between 
RhoA/ROCK and the PKB/eNOS pathway might exist. The aims of this part of the 
study are to investigate whether Rho/ROCK negatively regulates eNOS gene 
expression and enzymatic activity and if so what the underlying mechanisms are. 
1.       Effects of Rho/ROCK on eNOS gene expression.  
A previous study demonstrated that thrombin-mediated downregulation of 
eNOS gene expression via decreasing the eNOS mRNA stability could be prevented 
either by the Rho GTPase inhibitor C3 exoenzyme or by the Rho kinase or ROCK 
inhibitor Y-27632 in cultured HUVECs (Eto et al., 2001). This suggests that 
Rho/ROCK pathway plays an important role in eNOS gene expression. To further 
investigate the role of Rho/ROCK in the regulation of eNOS gene expression and the 
underlying mechanism, effects of an active or a dominant negative form of Rho or 
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ROCK on eNOS expression in HUVECs were analyzed using adenovirus-mediated 
gene transfer. For this purpose, the infectivity of HUVECs was first determined by 
infecting the cells with rAd-GFP. The expression of GFP was detected in about 100% 
of the HUVECs. Next, the HUVECs were infected with recombinant adenovirus 
expressing various transgenes and their effects on eNOS gene expression were 
analyzed by Western blot. All the transgenes were expressed as detected by Western 
blot using monoclonal anti-HA antibody 12CA5 (Figure. 1A). 
Figure 1: Effects of Rho/ROCK on eNOS gene expression. (A) HUVECs were infected with rAd 
expressing HA-tagged LacZ, active Rho (Rho63), dominant negative Rho (Rho19), active ROCK 
(CAT) and dominant negative ROCK (RB) as indicated, at titers ranging from 100 to 150 MOI, 
and incubated in 0.2% FCS RPMI-1640 supplemented with ECGS for 48 h. Cells were then 
extracted without any treatment and the expression of the transgenes were analyzed by Western 
blot (WB) using anti-HA antibody 12CA5. 
The effect of the transgenes on eNOS expression was analyzed by WB using 
anti-eNOS antibody. Figure 1B shows that ectopic expression of either active Rho 
(Rho63) or active ROCK (CAT) led to a decrease in eNOS expression, whereas 
ectopic expression of dominant negative mutant of Rho (Rho19) or ROCK (RB) 
abrogated downregulation of eNOS by thrombin (4U/ml, 48 h) (Figure 1C). These 
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data support our previous observation that the Rho/ROCK pathway plays an 
important role in eNOS expression. 
Figure 1: (B) The effect of the various transgenes on eNOS expression was examined by WB 
using anti-eNOS antibody.  (C) HUVECs were infected with rAd as indicated and serum-starved 
in 0.2% FCS culture medium for 24 hours followed by treatment with thrombin (4U/ml) for 48 
hours. The expression of eNOS was detected by WB. Actin in lower panels served as loading 
control. 
2.    Inactivation of PKB by Rho/ROCK.  
Furthermore, the mechanism by which the Rho/ROCK pathway downregulates 
expression of eNOS gene was investigated. It has been known that HMG CoA 
reductase inhibitors or statins plays an important role in the studies involving the 
pathway. Recently, simvastatin, an indirect inhibitor of Rho (Laufs et al., 2000), was 
shown to activate PKB (Kureishi et al., 2000), implicating a possible cross-talk 
between Rho and PKB pathway. It was therefore interesting to examine whether 
Rho/ROCK can inactivate PKB resulting in downregulation of eNOS expression. To 
do so, cultured HUVECs were infected with rAd expressing active or dominant 
negative mutant of Rho or ROCK and their effects on PKB activity were assessed by 
in vitro nonradioactive immunoprecipitation-kinase assay (Figure. 2A, panel a), as 
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well as by monitoring the phosphorylation of PKB at Thr-308 and Ser-473 (Figure 
2A, panel b).  
Figure 2: Active Rho or ROCK inhibits phosphorylation and activity of PKB without affecting 
p85-PI3K activity. (A) HUVECs were infected and extracted as described in Figure. 1A. Panel a 
shows the effect of Rho or ROCK mutants on PKB activity. 30 µg of lysates were used for 
immunoprecipitation with immobilized Akt 1G1 monoclonal antibody, and subjected to in vitro 
kinase assay using GSK-3 as substrate. Phosphorylation of GSK-3 was measured by western blot 
using phospho-GSK-3α/β (Ser21/9) antibody. Panel b: The extent of PKB phosphorylation was 
analyzed by WB using antibodies specific for phosphorylated Thr-308 or Ser-473 of PKB as 
indicated, whereas total PKB expression was detected by WB using antibodies that recognize 
PKB regardless of their phosphorylation status (lower panel). Shown are representative WB of 
five independent experiments. 
Quantification of the data is shown in the right panel. The extent of PKB 
phosphorylation was detected with an anti-Phospho-Akt (Thr-308 or Ser473) 
antibody. Ectopic expression of active Rho or ROCK decreased both PKB activity 
(Figure. 2A, panel a) and PKB phosphorylation at Thr-308 and Ser-473 without 
affecting PKB protein level (Figure. 2A, panel b), whereas the dominant negative 
mutant of Rho or ROCK did not significantly affect PKB activity or phosphorylation. 
These data provide evidence that there is indeed a cross-talk between Rho/ROCK and 
PKB pathway and that Rho/ROCK pathway negatively regulates PKB activation. As 
monitoring Ser-473 reflects PKB activity (Figure. 2A), the effects on PKB activity 
were therefore assessed by only monitoring Ser-473 for further studies.  
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 Evidence has been presented that adenovirus infection triggers activation of 
Phosphatidylinositol 3-kinase (PI3-K) pathway via interaction of the adenoviral 
penton base caspid with α/v integrins (Li et al., 1998, Li et al., 2000, Nemerow et al., 
1999). In order to demonstrate that the PKB activation upon adenoviral infection 
shown in Figure. 2A is PI3-K dependent, PI3-K inhibitor wortmannin was used to 
block PI3-K activation. In agreement with the established role of PI3-K in PKB 
activation, integrin-mediated PKB activation upon control adenoviral infection was 
effectively inhibited by wortmannin treatment (Figure. 2B)  
Figure 2: (B) HUVECs were infected as indicated and extracted 18 h post infection (p.i). To 
inhibit PI3-K, cells were treated with 250 nM wortmannin (WM) for 2 h before extraction. Cell 
lysates were assayed for PKB phosphorylation at Ser-473.  
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Figure 2: (C) Lanes 1 to 6, HUVECs were either left uninfected or were infected as indicated and 
extracted at 18 h p.i. Cell lysates were asayed for PKB phosphorylation at Ser-473 (panel a) and 
in vitro PI 3-kinase activity in anti-phosphotyrosine (PY) immunoprecipitates (panel b) as 
described in Materials and Methods. Quantification of signal intensities by using the everage of 
five independent experiments is shown in the right panels. Lanes 7 and 8, cell lysates prepared 
from untreated and PDGF-treated (50ng/ml of PDGF-BB for 10 min) hSMCs were included as 
positive control for PI 3-kinase activation. 
Next, was to determine whether activation of Rho/ROCK pathway inhibits 
PI3-K activation by analysing the effect of active Rho or ROCK on PI3-K activity in 
an in vitro PI 3-kinase assay in anti-phosphotyrosine immunoprecipitates (Figure. 
2Cb). Surprisingly, in contrast to the strong phosphorylation or activation of PKB 
upon adenoviral infection (Figure. 2Ca, compare lane 1 and lane 2) and inhibition of 
PKB phosphorylation or activation by Rho or ROCK (Figure. 2Ca, compare lane 3 
and 5 with lane 2), no obvious corresponding changes in PI 3-kinase activity could be 
observed, only a low basal PI 3-kinase activity could be detected (Figure. 2Cb, lanes 
1 to 6). To ensure that the whole procedures from cell extraction to 
immunoprecipitation with anti-phosphotyrosine antibody and lipid kinase reaction 
work properly to allow a detection of a PI 3-kinase activation, cell lysates were 
prepared from PDGF-stimulated hSMCs and included as a positive control for PI 3-
kinase activation (Figure. 2Cb, lanes 7 and 8). Given that the inhibition of PI 3-
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kinase with wortmannin resulted in inhibition of PKB phosphorylation or activation 
(Figure. 2B), these data suggest that in HUVECs and under our experimental 
condition, the basal PI 3-kinase activity is required for the PKB activity; however, 
PKB activation is unlikely to result from an activation of PI 3-kinase but may be from 
other mechanism such as inhbition of PTEN, inhibition of phosphatase 2A or even 
other unknown novel mechanism. The yet-to-be-clarified mechanism responsible for 
PKB activation would be therefore the target of Rho/ROCK to negatively regulate 
PKB activation shown here. 
3.    Effect of Rho/ROCK on eNOS phosphorylation.  
The fact that PKB activates eNOS by phosphorylating the enzyme at Ser-1177 
(Dimmeler et al., 1999, Fulton et al., 1999, Michell et al., 1999), and that Rho/ROCK 
suppresses PKB activation (Figure. 2), suggested that Rho/ROCK might negatively 
regulate eNOS activation, besides suppressing its own gene expression. To test this 
hypothesis, the effect of Rho or ROCK on eNOS phosphorylation at Ser-1177 was 
analyzed. Indeed, in parallel to the inhibition on PKB phosphorylation and activation 
(Figure. 2), eNOS phosphorylation was also suppressed upon expression of active 
Rho or ROCK (Figure. 3A).  
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Figure 3: Rho inhibits phosphorylation of PKB and eNOS in parallel via its downstream target 
ROCK. Cells were infected as indicated and extracted 18 hours post infection (p.i). A 
representative Western Blot from five (A) independent experiments is shown under various 
conditions as indicated. Quantification of the data is shown in the corresponding right panels. (A) 
The extent of eNOS phosphorylation was analyzed by WB using antibodies specific for 
phosphorylated Ser-1177 of eNOS (upper panel), whereas eNOS expression was analyzed by WB 
using antibodies that recognize eNOS regardless of its phosphorylation status (lower panel). In 
parallel, under the same experimental conditions, eNOS activity was monitored by analyzing the 
cellular NO production measured as the formation of its co-product [P14 PC]-citrulline. 
To verify that eNOS enzyme activity parallels its phosphorylation, eNOS 
activity was measured in parallel under the same experimental conditions by in vivo 
L-citrulline assay. In agreement with the previously demonstrated role of eNOS 
phosphorylation at Ser-1177 in activation of eNOS enzyme activity (Dimmeler et al., 
1999, Fulton et al., 1999, Michell et al., 1999), eNOS activity correlates well with the 
eNOS phosphorylation (Figure 3A, right panel), indicating that the modulation of the 
Rho/ROCK on eNOS phosphorylation indeed reflects their effects on eNOS activity. 
In contrast to the experiments shown in Figure 1B where cell lysates were prepared at 
48 hours post infection (p.i) and eNOS expression was clearly downregulated upon 
active Rho or ROCK expression, in these experiments the cell lysates were prepared 
at 18 hours p.i to ensure that the suppression of eNOS phosphorylation is not a 
consequence of downregulation of eNOS expression by Rho or ROCK. As shown in 
Figure 3A lower panel, there was no significant effect on eNOS expression yet at this 
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time point. Moreover, co-expression of the dominant negative ROCK (RB) prevented 
Rho63-mediated decrease in both PKB phosphorylation and eNOS phosphorylation 
(Figure. 3B).  
 
Figure 3: (B) The extent of eNOS and PKB phosphorylation was analyzed as described in Figure 
3A and Figure 2, respectively.  
 
To rule out the possibility that the reversal effect of RB on phosphorylation of 
PKB and eNOS is due to unexpected transcriptional effects on Rho63, the expression 
of Rho63 in the absence or presence of RB was determined by Western blot. No 
obvious difference was observed under this condition (Figure. 3C). We conclude that 
Rho not only downregulates eNOS expression (Figure. 1) (Eto et al., 2001, Laufs et 
al., 1999, Laufs et al., 1998), but it also inhibits eNOS phosphorylation and activity 
via its downstream target ROCK.  
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Figure 3: (C) The expression of HA-tagged LacZ, RB and Rho63 was detected by Western blot 
using monoclonal anti-HA antibody 12CA5.  
4.   Role of PKB in Rho-mediated downregulation of eNOS phosphorylation 
and expression.  
From the results above, it was of interest to determine whether Rho/ROCK 
inhibits eNOS gene expression and phosphorylation via inhibition of PKB. 
Accordingly, cells were co-infected with recombinant adenoviruses expressing a 
constitutively active or inactive mutant of PKB, and their effects on Rho63-mediated 
downregulation of eNOS phosphorylation and cellular NO production reflected by L-
citrulline production (extracts prepared at 18 hours p.i, Figure. 4A), as well as eNOS 
expression (extracts prepared at 48 hours p.i, Figure. 4C) were assessed. Ectopic 
expression of the active PKB (m/p), but not the inactive PKB (KA) restored eNOS 
phosphorylation in the presence of Rho63 (Figure. 4A). To ensure that the rescuing 
effect of m/p-PKB on eNOS phosphorylation in the presence of Rho63 is not due to 
unexpected transcriptional effects on Rho63, control Western blots were performed.  
HA-LacZ
HA-RB
HA-Rho63
C
rAd (18h p.i.)LacZ Rho63
RBRB
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Figure 4: Active PKB reversed Rho63-mediated inhibition of phosphorylation, but not of the 
expression of eNOS.  Cells were infected as indicated and the cell lysates were prepared 18 hours 
post infection for (A)/(B) or 48 hours p.i for (C). A representative Western Blot from five 
independent experiments is shown under various conditions as indicated. Quantification of the 
data using average of five independent experiments is shown in the corresponding right panels. 
(A) Effect of PKB on Rho63-mediated dephosphorylation of eNOS and PKB, and on cellular NO 
production measured as the formation of [P14 PC]-citrulline. (B) The expression of HA-tagged LacZ, 
active PKB (m/p), inactive PKB (KA) and Rho63 detected by Western blot using monoclonal 
anti-HA antibody 12CA5. 
As shown in Figure. 4B, no inhibitory effect of m/p-PKB on the expression of 
Rho63 was observed; suggesting that inactivation of PKB is indeed responsible for 
negative regulation of eNOS phosphorylation by Rho/ROCK pathway.  
Of note, in contrast to the effect of Rho/ROCK constructs on eNOS 
phosphorylation and cellular NO production which parallels each other as shown in 
Figure. 3A right panel, Figure. 4A reveals that active PKB restored eNOS 
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phosphorylation without restoring cellular NO production. As eNOS activity was 
monitored by measuring L-citrulline production in living cells with L-[P14PC]arginine, 
these data suggest that Rho/ROCK pathway may also downregulate other factors that 
affect cellular NO production such as the availability of the substrate arginine or 
eNOS cofactor through PKB-independent pathway. Moreover, in contrast to its 
rescuing effect on eNOS phosphorylation, m/p-PKB could not restore eNOS gene 
expression in the presence of Rho63 (Figure. 4C).  
Figure 4: (C) Effect of PKB on Rho63-mediated downregulation of eNOS gene expression. 
These observations indicate that Rho/ROCK pathway negatively regulates 
eNOS phosphorylation through inhibition of PKB pathway, whereas it downregulates 
eNOS gene expression via another yet to be identified pathway. 
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5.   Role of Rho and PKB pathways in thrombin-mediated downregulation 
of eNOS phosphorylation and expression.  
Finally, it was investigated whether the conclusions drawn above would also hold 
true for thrombin, a risk factor in the pathogenesis of cardiovascular disease that 
activates the Rho/ROCK pathway (Eto et al., 2001) (Figure. 5A). 
Figure 5: Role of Rho and PKB in thrombin-mediated downregulation of eNOS phosphorylation 
and expression. (A) Time course of Rho activation by thrombin. HUVECs were serum-starved 
for 24 hours and then treated with 4U/ml thrombin for indicated time. The cell lysates were 
subjected to pull-down assay of GTP-Rho as described in method. 
Treatment of HUVECs with thrombin (4U/ml) for 15 minutes decreased 
phosphorylation of eNOS and PKB in parallel without significantly affecting the 
protein level of eNOS or PKB (Figure. 5B). Moreover, inhibition of phosphorylation 
of eNOS or PKB by thrombin was reversed by ectopic expression of the dominant 
negative Rho (Rho19) or the active PKB (m/p) (Figure. 5B), suggesting that thrombin 
inhibits eNOS phosphorylation via RhoA which in turn inactivates PKB pathway. 
Consistent with the results shown in Figure 2B that active Rho and ROCK inhibited 
PKB phosphorylation and activity without having an effect on PI3-K activity, 
activation of Rho by thrombin inhibited PKB phosphorylation without suppression of 
PI3-K activity (Figure. 5B). Remarkably, thrombin even caused a slight activation of 
PI3-K and is not influenced by dominant mutant of Rho (Figure. 5B). These data 
support the hypothesis that inhibition of PKB phosphorylation and activity by 
___________________________________________________________________________Results 1 
 80 
Rho/ROCK pathway is not resulted from inhibition of its upstream PI3-K. 
Furthermore, in agreement with previous observations above, down-regulation of 
eNOS expression by thrombin (4U/ml, 48 hours) was prevented by the dominant 
negative Rho, but not by the active PKB (Figure. 5C).  
Figure 5: (B) Effect of dominant negative Rho (Rho19) and active PKB (m/p) on thrombin-
induced dephosphorylation of eNOS, PKB and p85-PI3K activity. Cells were infected and serum-
starved for 24 hours. The cells were then either untreated (-) or treated with thrombin (+) 15min. 
Figure 5: (C) Effect of Rho19 and m/p-PKB on thrombin-mediated downregulation of eNOS gene 
expression. Cells were infected and treated with thrombin for 48h. Shown are representative 
blots from three (5A) or five (5B and 5C) independent experiments. Quantification of the data is 
shown in the right panel. 
Taken together, the results confirm the observation obtained with Rho mutants 
and demonstrate that thrombin downregulates both eNOS expression and 
phosphorylation via Rho pathway, which inhibits PKB and subsequently eNOS 
phosphorylation but not eNOS expression.  
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DISCUSSION (PART1) 
In this study, it is demonstrated that Rho/ROCK not only downregulates eNOS 
expression, but it also inhibits eNOS phosphorylation and its activity. Moreover, there 
is evidence that inactivation of PKB by Rho/ROCK is responsible for the inhibition of 
eNOS phosphorylation but not the downregulation of eNOS gene expression. 
Furthermore, these conclusions are reinforced by the results obtained with thrombin. 
Concomitant with its ability to activate Rho/ROCK, thrombin suppressed the 
phosphorylation of PKB and eNOS, in addition to its downregulatory effect on eNOS 
expression. Although inhibition of both expression and phosphorylation of eNOS by 
thrombin is mediated by Rho/ROCK pathway, only the suppression of eNOS 
phosphorylation could be attributed to inactivation of PKB by thrombin.   
Rho GTPase has been shown to regulate a wide spectrum of cellular function 
(Van Aelst et al., 1997). Increasing evidence suggests a role of Rho-regulated cellular 
function in mediating cardiovascular pathologies such as smooth muscle 
hypercontraction (Shimokawa H et al., 2000), smooth muscle cell growth and 
migration that account for neointimal formation of stenosis (Seaholtz et al., 1999, Eto 
et al., 2000) and platelet aggregation (Missy et al., 2001, Nishioka et al., 2001). 
Moreover, in recent years, much has been learned about the role of Rho in modulating 
endothelial function. In the context of endothelial dysfunction, Rho has been reported 
to downregulate eNOS expression (Eto et al., 2001, Laufs et al., 1999, Laufs et al., 
1998) and is essential for the basal production of endothelin (ET)-1 (Hernandez-
Perera et al.,2000), a potent vasoconstrictor and mitogen that regulates vascular tone 
and remodeling (Levin ER 1995). In agreements with previous reports, it is 
demonstrated here that activation of Rho is sufficient to downregulate eNOS 
expression and is required for thrombin-mediated decrease in eNOS expression 
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(Figure.1). Moreover, in this study, we provide additional evidence for an important 
role of Rho in modulating PKB/eNOS pathway. The activation of Rho was shown 
either by ectopic expression of active mutant of Rho or by a pathologic stimulus 
thrombin, dramatically inhibited phosphorylation of eNOS in parallel to that of PKB 
(Figure. 2 and 3). Of interest, while thrombin-induced dephosphorylation of eNOS 
occurs within 15 min (Figure. 5B), it takes hours to days to achieve downregulation 
of eNOS expression (Figure. 5C and (Eto et al., 2001, Laufs et al., 1999, Laufs et al., 
1998)). The same is true with the constructs expressing active Rho or ROCK. Due to 
the fact that it takes at least more than 8 hours to express the transgenes, it is not 
known exactly how rapidly the dephosphorylation was induced upon Rho63 
expression. However, eNOS dephosphorylation could be already observed at 18 hours 
post-infection, at a time point when eNOS expression was not yet significantly 
affected (Figure. 3 and 4A). In this respect, signals such as thrombin would cause 
endothelial dysfunction via the activation of Rho that in turn leads to 
dephosphorylation or inactivation of eNOS and suppression of its gene expression. 
This mechanism may play an important role in acute coronary syndromes in patients 
with heart disease. 
To date, a number of downstream effector proteins of Rho have been 
identified (Aspenstrom 1999). Amongst, ROCK is the most extensively and well-
studied. Many of the Rho-regulated cellular functions have been shown to be 
mediated by ROCK, such as smooth muscle contraction (Amano et al., 1996, Kimura 
et al., 1996, Kureishi et al., 1997), cytoskeletal rearrangement and c-fos expression 
(Chihara et al.,1997), and cytokinesis (Yasui et al.,1998). We show here that Rho-
induced dephosphorylation of PKB and eNOS is also mediated by ROCK. This 
conclusion is based on the observations that the active ROCK led to 
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dephosphorylation of both PKB and eNOS (Figure. 2 and Figure. 3A), the dominant 
negative ROCK prevented Rho63-mediated inhibition of PKB and eNOS 
phosphorylation (Figure. 3B). Important evidence we provide in this report is the 
cross-talk between Rho/ROCK and PKB. The importance of this finding should be 
underscored by the fact that PKB serves as a multifunctional regulator of cell survival, 
growth and glucose metabolism (Datta et al.,1999). With respect to its cardiovascular 
functions, PKB plays a critical role in endothelial cell survival (Fujio et al., 1999, 
Gerber et al., 1998) and promotes angiogenesis (Dimmeler et al., 1999,Kureishi et al., 
2000) mediated by vascular endothelial growth factor (VEGF), in addition to its 
involvement in controlling vasomotor activity via regulating eNOS pathway as 
mentioned above. Here we demonstrate that the cross-talk between Rho/ROCK and 
PKB pathways is responsible for Rho-mediated eNOS dephosphorylation. Two lines 
of evidence supported the involvement of PKB in Rho/ROCK-mediated inhibition of 
eNOS phosphorylation. The first evidence came from experiments using 
constitutively active mutants. The data in Figure 2 and 3 show that dephosphorylation 
of PKB and eNOS by active Rho or ROCK closely parallel one another. The second 
piece of evidence is provided by the rescue experiment in which an active PKB, but 
not an inactive PKB, restored phosphorylation of eNOS in the presence of active Rho 
(Figure. 4A). Since evidence has been presented that eNOS phosphorylation by PKB 
lead to an increased NO production, the active PKB restored eNOS phosphorylation 
in the presence of active Rho mutant without restoring cellular NO production 
(Figure. 4A). Taking into account that eNOS activity was monitored by measuring 
the cellular NO production in living cells with L-[P14 PC]arginine, and that the effects of 
Rho and ROCK mutants on eNOS phosphorylation and cellular NO production 
parallel each other (Figure. 3A), a probable explanation would be that Rho/ROCK 
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pathway may also downregulate other factors such as the availability of the substrate 
arginine or eNOS cofactor that are necessary for a normal cellular NO production, but 
through other pathway(s) independent of PKB. 
While the role of PKB in eNOS phosphorylation leading to an increased NO 
production is well-documented and established, little is known about an involvement 
of PKB in eNOS gene expression. In view of the fact that PI3-K was reported to be 
involved in eNOS gene expression (Cieslik et al., 2001, Kuboki et al., 2000) and PKB 
is a well-characterized downstream signaling of PI3-K, it is important to point out that 
active PKB did not rescue Rho63- or thrombin-mediated eNOS gene downregulation 
(Figure. 4C and 5C), indicating that PKB is not required for Rho63 or thrombin to 
downregulate eNOS expression. However, this does not rule out a role of PKB in the 
regulation of eNOS gene expression. One possibility could be that PKB does not play 
a role in the regulation of eNOS mRNA stability by thrombin or Rho, yet is involved 
in eNOS transcriptional regulation as reported in one study regarding regulation of 
eNOS gene expression by PI3-K (Cieslik et al., 2001). 
Regarding the role of PI3-kinase in Rho/ROCK-mediated downregulation of 
PKB phosphorylation and activity by active mutants of Rho/ROCK, the data suggest 
that the inhibition of PKB activity by Rho/ROCK is unlikely to result from inhibition 
of PI3-kinase activity since the PKB activation upon adenoviral infection or the 
inhibition of PKB activation by active Rho/ROCK is not accompanied by 
corresponding changes in PI3-kinase activity (Figure 2C). This is noteworthy in view 
of the fact that PI3-kinase is strongly activated upon adenoviral infection in the 
human colon carcinoma cell line SW480 (Li et al., 1998, Li et al., 2000). Thus, 
although the basal PI3-kinase activity is required for PKB phosphorylation and 
activity in HUVECs under this experimental conditions (Figure 2B), the PKB 
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activation probably did not result from PI3-kinase activation but may be from other 
mechanisms such as inactivation of PTEN, inactivation of phosphatase 2A, or even 
some other unknown novel mechanism. Which mechanism accounts for the PKB 
activation and hence be the target of Rho/ROCK to negatively regulate PKB 
activation as reported in this study remains unknown.  
The data presented here are summarized as follows: a stimulus that activates 
Rho/ROCK pathway would lead to dephosphorylation of eNOS while simultaneously 
suppressing its expression by decreasing its mRNA stability to achieve rapid and 
long-term decrease in NO production (Figure 6).  
 
 
 
 
 
 
 
 
 
 
Figure 6: Activation of RhoA/ROCK for example, by thrombin, on one hand is responsible for 
the downregulation of eNOS gene expression by destabilizing eNOS mRNA, independently of 
PKB inhibition, which persists through a long period of time. In addition to this effect, it also 
inhibits phosphorylation of eNOS via the inactivation of PKB giving rise to a rapid effect. Both of 
these chronic and acute effects lead to a decrease in NO production. 
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Whereas inhibition of PKB by Rho/ROCK is responsible for the negative 
regulation of eNOS phosphorylation, the downregulation of eNOS expression is 
attributed to another yet-to-be-identified pathway. An important task will be to further 
elucidate the mechanism by which Rho/ROCK inactivates PKB. In addition, the 
impact of the cross-talk between the two pathways on other PKB-regulated cellular 
functions should be a goal worthwhile to follow-up for future research. 
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Part 2: RhoA/ROCK Pathway Stimulates Human Endothelial Arginase Activity: 
Implications for Atherosclerotic Endothelial Dysfunction. 
Besides co-factors, gene expression level, post-translational modifications, the 
availability of the substrate L-arginine is also involved in the regulation of NO 
bioavailability (Hallemeesch et al., 2002). Increasing evidences have demonstrated 
that arginase; an enzyme in the urea cycle competes with NOS for the substrate L-
arginine, which leads to a reduction in NO production (Chang et al., 1998, Zhang et 
al., 2001). An increased arginase activity has been implicated in hypertension, 
aging-associated endothelial dysfunction, diabetic erectile dysfunction and pulmonary 
artery hypertension (Bivalacqua et al., 2001, Berkowitz et al., 2003). Clinical and 
animal studies with L-arginine supplementation failed to show consistent results in the 
improvement of endothelial dysfunction in atherosclerosis (Chen et al., 2003). It is 
also to notice that eNOS expression in most atherosclerotic animal models either 
showed no changes or even an increase. We investigated whether arginase could play 
a role in endothelial dysfunction in atherosclerosis. The underlying mechanisms of 
increased arginase activity were also studied. 
1. Thrombin stimulates arginase activity in human endothelial cells 
Stimulation of HUVECs with various concentrations of thrombin (0.1 U/ml to 
2 U/ml) for 24 hours enhanced arginase activity with the maximum effect at the 
concentration of 1 U/ml (1.9-fold increase above control, n=9, P<0.001, Figure. 1). 
This result demonstrated that thrombin which upregulates RhoA/ROCK could induce 
arginase activity in human endothelial cells. Since the maximum effect was observed 
at 1U/ml, this concentration  of thrombin was used in the following experiments.  
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Figure 1. Thrombin dose-dependently stimulates arginase activity in HUVECs. HUVECs were 
serum starved for 24 h, followed by treatment with various concentrations of thrombin as 
indicated for 24 h. Cells were then subjected to arginase activity assay. Columns represent mean 
± SEM of 9 experiments (*P<0.05, **P<0.01, ***P<0.001 vs. untreated cells, i.e. dose zero). 
The cells were then stimulated with thrombin (1 U/ml) at different time points 
from 5 minutes to 24 hours. As demonstrated in Figure. 2, a significant increase in 
arginase activity was observed after 18 to 24 hours exposure of the cells to thrombin 
with a maximum effect at 24 hours (1.9-fold, n=3, p<0.001). 
Figure 2. Time course of thrombin-induced arginase activity. HUVECs were treated with 
thrombin (1 U/ml) for different times as indicated, extracted and assayed for arginase activity. 
Columns represent mean ± SEM of 3 experiments (*P<0.05, ***P<0.001 vs. untreated cells, i.e. 
time zero). 
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2. The role of RhoA /ROCK in regulation of arginase activity 
As shown in Figure. 3A, stimulation of arginase activity by thrombin (1 U/ml, 
24 hours) in endothelial cells was inhibited by HMG CoA reductase inhibitor 
fluvastatin (1 µmol/L) or ROCK inhibitor Y-27632 (10 µmol/L) at the concentrations 
that inhibit RhoA or ROCK as shown by a previous study (Barandier et al., 2003) 
Neither thrombin nor the inhibitors significantly influenced arginase II protein level 
(Figure. 3B, arginase I was not detectable in the cells).  
Figure 3. Thrombin induces arginase activity via RhoA/ROCK. (A) stimulation of arginase 
activity by thrombin (1 U/ml) was inhibited by pretreatment of the cells with fluvastatin (FS, 1 
µmol/L) or Y-27632 (Y, 10 µmol/L) for 1 h 30 minutes or (C) by C3 exoenzyme (20 µg/mL, 20 
hours) or HA-1077 (10 µmol/L, 1 hour). (B) A representative blot revealing arginase II 
expression was not modified by various substances used in panel A (the expression of arginase I 
was not detectable in HUVECs). Columns represent mean ± SEM of 5 independent experiments. 
(D) eNOS protein level was significantly decreased after 6 hours of exposure to thrombin (1 
U/ml). ***P<0.001 for comparison between groups as indicated or vs. control (0 h) in panel D. 
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Stimulation of arginase activity by thrombin was also inhibited by C3 
exoenzyme (20 µg/mL) or by another ROCK inhibitor HA-1077 (10 µmol/L, Figure. 
3C; n=5, p<0.001 vs. thrombin alone), further demonstrating the role of Rho/ROCK 
pathway in thrombin-stimulated arginase activity in the cells. It is to notice that 
exposure of the cells to thrombin at 1 U/ml time-dependently suppressed eNOS 
protein level over 24 hours, an effect that was significant at 6 hours (Figure. 3D).  
Furthermore, adenovirus-mediated expression of the active mutant of RhoA 
(Rho63) or ROCK (CAT) enhanced arginase activity in the cells, whereas the 
negative mutant of RhoA (Rho19) or ROCK (RB) alone had no effect (Figure. 4A)  
Figure 4. Active RhoA or ROCK stimulates arginase activity. (A) HUVECs were infected with 
recombinant adenovirus (rAd) expressing HA-tagged LacZ, active RhoA (Rho63), dominant 
negative RhoA (Rho19), active ROCK (CAT) or dominant negative ROCK (RB) as indicated, at 
titers ranging from 100 to 150 multiplicity of infection (MOI), and incubated in 0.2% FCS 
RPMI-1640 supplemented with ECGS for 48 h. Cells were then extracted without any treatment 
and assayed for arginase activity 
Again, the arginase II protein level in the cells were not affected by the 
mutants (Figure. 4B, n=7). The increase in arginase activity stimulated by the active 
Rho63 mutant was abolished by the two different ROCK inhibitors Y-27632 (10 
µmol/L) or HA-1077 (10 µmol/L, Figure. 4C). The inhibitors alone had no 
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significant effects on the basal arginase activity (Figure. 4C). It was previously 
shown (Ming et al., 2002) that eNOS protein level is markedly down-regulated by the 
active RhoA or ROCK mutants 24 hours after transduction. 
Figure 4. Cells stimulated with active RhoA or ROCK subjected to Western blot for arginase 
expression. A representative blot revealing arginase II expression is shown in B. Columns 
represent mean ± SEM of 7 independent experiments. 
Figure 4. Active RhoA or ROCK stimulates arginase activity. (C) Rho63 induced activation of 
arginase activity was inhibited by the ROCK inhibitors Y-27632 (Y) or HA- 1077 (HA). 
***P<0.001 for comparison between groups as indicated or vs. LacZ. 
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3. Increased arginase activity and RhoA expression in atherosclerosis 
Given the above observations, it was tested whether arginase activity is 
increased in atherosclerosis. ApoEP-/-P atherosclerotic mice were used for this purpose. 
Indeed, ApoEP-/-P mice fed with a cholesterol rich diet for 4 months developed 
atherosclerotic lesions throughout the aorta, (Barton et al., 1998) and showed a 
significant higher arginase activity than aortas isolated from age-matched wild type 
mice (1.5-fold increase, n=5, p<0.01, Figure. 5A), In addition, the arginase II protein 
level was comparable in the aortas of the two groups and arginase I protein was not 
detectable in the mice aortas. Interestingly, RhoA protein level was remarkably 
increased (4-fold) in the aortas of ApoE P-/-P mice as compared to wild type animals 
(Figure. 5B). 
Figure 5. Increased arginase activity and RhoA level in atherosclerotic aortas of ApoE- /- mice: 
The isolated aorta was cut in two sections. One section was homogenized and sonicated in 
arginase lysis buffer for analysis of arginase activity (A), the other section in extraction buffer for 
analysis of RhoA expression by Western blot (B). *P<0.05 and **P<0.01 vs. WT. 
 
 
A. B 
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4. Arginase and eNOS activity 
The role of arginase in regulating eNOS activity was further investigated. In 
HUVECs, eNOS activity as measured by L-citrulline production was blunted by 
eNOS inhibitor L-NAME (0.1 mmol/L) and also by thrombin (1 U/ml, 24 hours, n=5, 
50±9% decrease, P<0.001, Figure. 6A). Co-treatment of the cells with arginase 
inhibitor L-norvaline (20 mmol/L, 24 hours) (Chang et al., 1998), however, did not 
significantly reverse eNOS activity (Figure. 6A).  
Figure 6: Regulation of eNOS activity by arginase: (A) In cultured HUVECs, the eNOS inhibitor 
L-NAME (LN, 0.1 mmol/L) or thrombin (Thr, 1 U/ml, 24 hours) decreased eNOS activity as 
measured by L-citrulline production, which was not significantly reversed in the presence of 
arginase inhibitor L-norvaline (20 mmol/L, 24 hours, n=5). 
In mouse aortas, L-arginine (1 mmol/L) caused vasoconstriction (in contrast to 
rats in which L-arginine caused vasorelaxation) that was more pronounced in ApoEP-/- P 
(38±6%) than in wild type animals (17±4%, n=5, p<0.01, Figure. 6B).  
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Figure 6: (B) In aortic rings pre-contracted with norepinephrine (0.3 µmol/L), L-arginine (1 
mmol/L) caused a more pronounced vasoconstriction in ApoEP-/- P mice than in wild-type (WT) 
animals. In the presence of arginase inhibitor L-norvaline the contractions were converted to a 
greater vascular relaxation in ApoEP-/- P mice than in WT animals (n=5). 
However, eNOS expression was significantly higher in ApoEP-/-P than in wild type mice 
(Figure. 6C, p<0.05). Remarkably, the contraction was converted to a more 
pronounced relaxation by the arginase inhibitor Lnorvaline (20 mmol/L, 1 hour) in 
atherosclerotic ApoEP-/-P mice (-21±5%) than in wild type animals (-6±2%, Figure. 6B, 
n=5, p<0.001). 
Figure 6: (C) eNOS expression was significantly higher in ApoEP-/- P mice than in the WT animals. 
*P<0.05, **P<0.01 and ***P<0.001 vs. control or WT. 
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DISCUSSION (PART 2) 
Emerging evidence demonstrates that arginase is present in various cell types 
and is involved in negative regulation of NO production as reported in macrophages 
(Modolell et al., 1995, Morris et al., 1998, Gotoh et al., 1999) and endothelial cells 
(Zhang et al., 2001, Buga et al., 1996, Li et al. 2001). This study demonstrates that in 
human endothelial cells, arginase activity is significantly induced by thrombin. The 
induction of arginase activity can be inhibited by the HMG-CoA reductase inhibitor 
fluvastatin, which inhibits RhoA activation by geranylgeranylation of the enzyme 
(Laufs et al. 2000), and also by C3 exoenzyme which inactivates RhoA by ADP 
ribosylation (Aktories, 1997). Moreover, inhibition of ROCK, a downstream effector 
of RhoA, either by Y-27632 or HA-1077 abolished the thrombin’s effect, suggesting 
that thrombin stimulates arginase activity in human endothelial cells through 
RhoA/ROCK pathway. This conclusion is supported by the experiments showing that 
adenovirus-mediated ectopic expression of the constitutively active mutant of RhoA 
(Rho63) or ROCK (CAT), but not the negative mutants, significantly enhanced 
arginase activity in the cells. Furthermore, the effect of Rho63 was abolished by the 
ROCK inhibitor Y-27632 or HA-1077. 
 Two isoforms of arginases namely arginase I and II were reported to be 
expressed in vascular endothelial cells. In endothelial cells of porcine coronary 
arterioles and rat aortas, arginase I is constitutively expressed, (Zhang et al., 2001), 
Buga et al., 1996) whereas arginase II is inducible in response to lipopolysaccharide 
or cytokines (Buga et al., 1996). This study, however, showed abundant basal level of 
arginase II, whereas arginase I was not detectable in HUVEC, suggesting that 
arginase II is the major isozyme in HUVECs. It is to note that neither thrombin nor 
the active mutants of RhoA/ROCK did modulate arginase II expression (arginase I is 
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not inducible in the cells), suggesting that activation of arginase by thrombin or active 
RhoA/ROCK mutants occurs at the level of enzyme activity rather than on gene 
expression. Similar findings were also reported in rat endothelial cells, where 
expression of arginases was not modified by cytokines, although the enzymatic 
activity was stimulated (Suschek et al.  2003). It is conceivable that the enzyme might 
be modified biochemically by RhoA/ROCK pathway, that either alters the enzymatic 
activity or the affinity of the enzyme to its substrate. A third isoform of arginase 
might exist in endothelial cells and cannot be ruled out under this experimental 
condition. This aspect certainly warrants further investigation. Furthermore, it is 
demonstrated here that arginase enzymatic activity was significantly increased in 
atherosclerotic aortas of ApoEP-/-P mice. The higher arginase activity in the 
atherosclerotic aortas was associated with higher RhoA protein level suggesting a role 
of RhoA in upregulation of arginase activity. A definite characterization of the role of 
RhoA in stimulation of arginase activity in atherosclerosis in vivo could not be 
performed at this stage due to lack of specific RhoA inhibitors applicable in living 
mice. Nevertheless, the results obtained from cultured HUVECs support the role of 
RhoA in stimulation of arginase activity. 
Similar to cultured HUVECs, no difference in arginase II expression was 
observed between control mice and atherosclerotic ApoEP-/-P mice, and arginase I was 
not detectable in the mice aortas, suggesting an upregulation of arginase II enzymatic 
activity in atherosclerosis. 
Previous studies have indicated an important role of increased arginase 
activity, even a moderate increase of 1.5 to 2-fold, in endothelial dysfunction in aged 
rats and in human diabetic erectile dysfunction (Bivalacqua et al. 2001, Berkowitz et 
al.  2003). Then, the role of increased arginase activity in regulating NO production in 
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cultured endothelial cells and in atherosclerotic aortas of ApoEP-/-P mice was further 
investigated. In HUVECs treated with thrombin, eNOS activity was significantly 
reduced. However, this reduction of eNOS activity was not significantly reversed in 
the presence of arginase inhibitor L-norvaline. It is most likely due to the fact that 
eNOS protein level was simultaneously suppressed by thrombin, as demonstrated by 
Figure 3D and also by other previous studies (Eto et al. 2001, Ming et al. 2002). 
Alternatively, inhibition of co-factors of eNOS by thrombin might also be involved. 
Surprisingly, L-arginine induced vasoconstriction in mice aorta, which 
contrasts the observation in rats (Berkowitz et al. 2003) and humans (Creager et al. 
1992), where it evoked vascular relaxation. The contraction induced by L-arginine is 
much more pronounced in atherosclerotic ApoEP-/-P mice compared to control animals. 
The results may implicate that in the mice aortas, particularly in the atherosclerotic 
ApoEP-/-P aortas, L-arginine may be metabolized by arginase to certain vasoconstrictive 
intermediate products. Most interestingly, the contractions were converted to 
relaxations in the presence of the arginase inhibitor L-norvaline, an effect which was 
significantly greater in atherosclerotic ApoEP-/-P mice compared to wild type animals, 
demonstrating a dominant role of increased arginase activity in regulation of 
endothelial NO production in atherosclerosis. Most notably, eNOS gene expression is 
significantly higher in atherosclerotic aortas (see Figure 6C), further supporting the 
concept that endothelial dysfunction in atherosclerosis is due to a decreased NO 
bioavailability (d’Uscio et al. 2001). The higher eNOS expression in atherosclerosis 
would make an efficient NO production possible, when arginase is inhibited. This 
may implicate arginase as a potential therapeutic target for treatment of 
atherosclerotic vascular disease. It is also important to point out that eNOS protein 
level was not suppressed in atherosclerotic aortas of ApoEP-/-P mice despite higher 
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RhoA level in these blood vessels. It is conceivable that the suppressing effect of 
RhoA on eNOS protein expression might be compensated by other mechanisms in 
vivo. 
In conclusion, this study provides evidence for the role of RhoA/ROCK 
pathway in stimulation of arginase activity in human endothelial cells. The increased 
arginase activity is associated with higher RhoA expression and is involved in 
endothelial dysfunction in atherosclerosis. Targeting arginase in the vasculature may 
represent a novel therapeutic strategy for treatment of atherosclerosis.
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Part 3: Rho/ROCK Pathway Stimulates Endothelial Tissue Factor Expression: 
Inhibition by High-Density Lipoprotein (HDL). 
 Thrombosis at the site of atherosclerotic plaque disruption is the principal 
cause of acute coronary syndromes (Moons et al., 2002, Suefuji et al., 1997). Tissue 
factor (TF) plays a crucial role in the initiation of thrombus formation. In 
atherosclerosis, TF, a 47 kDa integral membrane protein, is expressed in large 
amounts in macrophages, smooth mscle cells but negligibly in endothelial cells 
(Wilcox et al., 1989). Studies provide evidence that RhoA and p38 PmapkP pathways 
positively regulate TF expression (Ishibashi et al., 2003), whereas PKB/Akt/eNOS 
pathway negatively regulates its expression in endothelial cells (Eto et al., 2002).  
 The protective effects of high-density lipoprotein (HDL) are well-
documented and considered to be attributed to reverse cholesterol transport. Emerging 
evidence suggests that HDL exerts its anti-atherosclerotic effects also via 
cholesterol-independent mechanisms including improvement of endothelial function 
(Yuhanna et al., 2001, Mineo et al., 2003, O’Connell et al., 2001). In isolated in vitro 
reaction assay, HDL has been shown to inhibit activation of coagulation factor X by 
factor VIIa and TF purified from placenta (Carson, 1981). These studies suggest a 
modulatory role of HDL in hemostasis. Therefore, this study aimed to investigate if 
HDL inhibits TF expression in activated endothelial cells by interfering with 
RhoA/ROCK, p38 Pmapk P and/or PI3K/PKB/eNOS pathways. 
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1. rHDL inhibits thrombin-induced TF expression.  
Stimulation of HUVECs with thrombin (4 U/ml) for 4 hours markedly 
increased TF protein level (Figure. 1A, upper panel, n=7) confirming the results of a 
previous study by Eto et al. (Eto et al. 2002). The induction of endothelial TF level by 
thrombin was significantly inhibited by rHDL (0.1 mg/ml, 43% inhibition Figure. 
1A, lower panel, n=7; p<0.001), whereas rHDL alone had no significant effect on the 
basal TF level in the cells.  
Figure. 1: rHDL inhibits endothelial tissue factor (TF) expression by thrombin: In HUVECs (A) 
as well as human aortic endothelial cells (B, HAEC, n=3) thrombin (Thr, 4 U/ml; 4 hours) up-
regulated TF protein level which was significantly inhibited by rHDL (0.1 mg/ml), while rHDL 
alone had no significant effect on the basal level of TF expression. * p<0.001 vs. Thr. 
HDL isolated from human plasma also inhibits thrombin-induced TF expression. 
Similar to HUVECs, in cultured human aortic endothelial cells, up-regulation of TF 
protein level by thrombin (4 U/ml, 4 hours) was also reduced by rHDL (0.1 mg/ml, 
47% inhibition, Figure. 1B, n=3, p<0.001). Due to the greater availability of the 
material, the subsequent experiments were performed in HUVECs with rHDL. 
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2. Effect of rHDL on thrombin-induced activation of RhoA.  
Since RhoA has been demonstrated to be involved in thrombin-mediated 
induction of TF expression in endothelial cells (Eto et al. 2002, Ishibashi et al. 2003), 
we analysed whether rHDL interferes with RhoA activation.  
Figure. 2:  rHDL inhibits endothelial tissue factor (TF) expression via inhibition of RhoA: (A) 
Pull-down assay shows that thrombin (Thr, 4 U/ml; 15 minutes) activated RhoA, (Rho-GTP) 
which was blocked by pre-incubation of the cells with rHDL (0.1 mg/ml, n=5). (B) Adenoviral 
expression of active RhoA mutant Rho63 enhanced endothelial TF expression (n=5). (C) The 
expression of transgenes of LacZ, Rho63 and Rho19 was shown by Western blot using anti-HA 
antibody.   *p<0.001 vs. control, †p<0.01 vs. Thr. 
Activation of RhoA by thrombin (4 U/ml, 15 minutes) was inhibited by rHDL (0.1 
mg/ml, n=5, p<0.01, Figure. 2A). The role of RhoA in the induction of TF was 
further demonstrated by the experiment showing that adenoviral expression of the 
constitutively active RhoA mutant Rho63 (24 hours post-infection) enhanced 
endothelial TF expression, while Rho19, the negative mutant had no effect on the 
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basal TF expression (n=5, Figure. 2B). Transgene expression was shown in Figure 
2C. 
3. Effect of rHDL on thrombin-induced activation of p38 PmapkP.  
We analysed whether rHDL reduces endothelial TF protein level by interfering 
with p38 Pmapk P which has been shown to be a positive regulatory mechanism of TF 
expression in endothelial cells (Eto et al. 2002, O’Reilly et al. 2003). Pre-incubation 
of the cells with rHDL (0.1 mg/ml) for 60 minutes did not significantly affect the 
activation of p38Pmapk P (phosphorylation at T-180/Y-185) in response to thrombin (4 
U/ml, 15 minutes, n=5, Figure. 3), although rHDL significantly inhibited thrombin-
induced TF expression under this condition.  
Figure 3: rHDL did not inhibit activation of p38PmapkP: Phosphorylation of p38PmapkP was significantly 
enhanced by thrombin (Thr, 4 U/ml, 15 minutes), which was not affected by rHDL (0.1 mg/ml, 
n=5). *p<0.001 vs. control.  
4. rHDL activates PI3K/Akt/eNOS pathway.  
Initial experiments with different concentrations of rHDL (0.01 to 1.0 mg/ml) 
demonstrated that rHDL at the concentration of 0.1 mg/ml gives the maximal 
activation of Akt and eNOS. Stimulation of the cells with rHDL (0.1 mg/ml) over 60 
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minutes induced a 1.7-fold increase in Akt phosphorylation at serine-473 (Figure. 4A, 
n=6, p<0.05). Activation of Akt by rHDL (0.1 mg/ml, 60 minutes) was abolished by 
the PI3K inhibitor, wortmannin (0.1µmol/L, Figure 4A, p<0.01).  
Figure 4: rHDL activates PI3K/Akt/eNOS pathway: (A) rHDL (0.1 mg/ml) phosphorylated Akt 
at serine-473, which was inhibited by the PI3K inhibitor wortmannin (WM, 0.1 mmol/L, p<0.05; 
n=6). (B) rHDL also stimulated phosphorylation of eNOS at serine-1177 and L-citrulline 
production, which was blocked by wortmannin (WM, 0.1 mmol/L, p<0.01; n=6). *p<0.05 vs. 
control, **p<0.01 vs. control, †p<0.05 vs. rHDL, ††p<0.01 vs. rHDL. 
In parallel with Akt activation, rHDL stimulated eNOS phosphorylation at 
serine-1177 (1.5-fold increase) reaching the maximum at 30 minutes (Figure. 4B). 
eNOS phosphorylation at serine-1177 was correlated with an increased L-citrulline 
production (1.9-fold, n=6, p<0.05) which was inhibited by wortmannin (0.1 µmol/L, 
Figure. 4B, n=6, p<0.01). 
5. rHDL prevents thrombin-induced TF expression involving PI3K but not 
Akt/eNOS.  
The inhibitory effect of rHDL on TF expression induced by thrombin (4U/ml, 
4 hours) was fully reversed by the PI3K inhibitors wortmannin (0.1 µmol/L, Figure. 
5A, n=3, p<0.01) or LY-294002 (1 µmol/L, n=5, p<0.01, Figure. 5B).  
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Figure 5: rHDL inhibits tissue factor (TF) expression via PI3K: Inhibition of TF expression in 
response to thrombin (4 U/ml, 4 hours) by rHDL (0.1 mg/ml) was abolished by the PI3K 
inhibitors wortmannin (0.1 µmol/L, n=3) (A) and LY-294002 (LY, 1 mmol/L, n=5, B). 
Moreover, adenoviral expression of a constitutively active PI3K (rCD2-p110) 
significantly reduced TF protein level stimulated by thrombin (Figure. 5C, n=4, 
p<0.05). The p110 transgene expression was demonstrated by immunobloting using 
anti-CD2 antibody (Figure. 5D, lane 2; lane 1 are cells expressing HA-tagged LacZ 
which is therefore not detectable with anti-CD2 antibody).  
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Figure 5: Adenoviral expression of the PI3K active mutant p110 reduced thrombin-induced TF 
up-regulation (n=4, C). The transgene expressions of CD2-tagged p110 (rCD2-p110) was 
demonstrated by immunoblotting using anti-CD2 antibody (D, Lane 2. Lane 1 is the HA-tagged 
LacZ expressing cell which is not detectable under this condition. p110 appears larger on the 
SDS-PAGE gel due to the tagged rCD2). *p<0.05 vs. thrombin, †p<0.001 vs. Thr+rHDL, 
††p<0.01 vs. Thr+rHDL. 
In contrast to the active PI3K mutant, adenoviral expression of a constitutively 
active Akt mutant (m/p-Akt) enhanced the up-regulation of TF expression stimulated 
by thrombin (Figure. 6A, n=3, p<0.05). The transgene expression of m/p-Akt and 
LacZ was demonstrated by immunoblotting using monoclonal anti-HA antibody 
(Figure. 6B).  
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Figure 6: rHDL inhibits tissue factor (TF) expression independent of Akt/eNOS: (A) Adenoviral 
expression of the active Akt mutant (m/p) further enhanced the stimulation of TF level by 
thrombin. (B) The expression of transgenes of HA-tagged LacZ (Lane 1) and m/p (Lane 2) was 
demonstrated by immunoblotting using anti-HA antibody. 
The role of Akt on TF expression was further investigated with the negative 
Akt mutant, Akt-KA whose expression was demonstrated by immunoblotting on 
Figure. 6C.  
An in vitro Akt kinase assay revealed that Akt was inhibited by ectopic 
expression of Akt-KA (Figure. 6D, panel a and c), indicating that Akt-KA functions 
as dominant negative mutant in the cells. It is also important to note that thrombin (4 
U/ml, 4 hours) reduced Akt activity which was reversed in the presence of rHDL 
(0.1mg/ml), and this recovering effect of rHDL on Akt activity was abolished by the 
dominant negative Akt-KA mutant (Figure. 6D, panel a and c).  
___________________________________________________________________________Results 3 
 107 
Figure 6: C, Expression of transgenes of HA-tagged LacZ (B and C, lane 1), the active m/p-Akt 
mutant (B, lane 2), and the negative Akt mutant (KA; C, lane 2) was demonstrated by 
immunoblotting using anti-HA antibody. Da, In HUVECs expressing LacZ control gene, basal 
Akt activity (lane 1) measured by phosphorylation of GSK-3 (p-GSK-3) as substrate was 
suppressed by thrombin (Thr 4 U/mL, 4 hours, lane 2), which was reversed in the presence of 
rHDL (0.1 mg/mL, lane 3). Expression of the negative Akt-KA mutant inhibited Akt activity 
(lane 4), which remained low by thrombin treatment (lane 5) and could not be reversed by rHDL 
(lane 6). Db, In HUVECs expressing LacZ control gene, no significant basal TF expression was 
observed (lane 1), but it was markedly upregulated by thrombin (4 U/mL, 4 hours, lane 2) 
reduced by rHDL (0.1 mg/mL, lane 3). Negative Akt-KA mutant alone had no effect on basal TF 
expression (lane 4) but reduced thrombin’s effect (lane 5) and did not reverse rHDL’s inhibitory 
effect on TF expression (lane 6). Tubulin expression was used to ensure equal protein loading. 
Quantification of the data from Da and Db is shown in Dc. 
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In line with the effect of the active Akt-m/p mutant which enhanced TF up-
regulation by thrombin (Figure. 6A), Akt-KA reduced TF up-regulation by thrombin 
and did not reverse the inhibitory effect of rHDL on TF expression, although neither 
active nor negative Akt mutants alone exerted any effect on basal TF expression in the 
cells (Figure. 6A and Figure. 6D, panel b and c).  
 
Figure 6: E, eNOS inhibitor L-NAME, (100 µmol/L, n=3) did not affect thrombin’s effect on TF 
expression. *P<0.05 vs Thr alone in A and E; *P<0.05, **P<0.01, and ***P<0.001 between the 
groups in D. Figure 7: Adenoviral expression of the active PI3K (rCD2-p110) did not inhibit 
RhoA activation by thrombin. Infection of HUVECs with the active mutant of PI3K, p110, did 
not inhibit RhoA activity induced by thrombin (4 U/ml, 15 minutes). *p<0.05 vs. LacZ. 
Moreover, inhibition of eNOS by L-NAME (100 µmol/L) did not affect 
rHDL's effect, and L-NAME alone did not modify basal level of TF expression in the 
cells (Figure. 6E, n=3). Note that viral expression of the active PI3K mutant p110 did 
not inhibit activation of RhoA by thrombin (4U/ml, 15minutes, n=6, Figure. 7). 
 
 
 
 
 
 
Figure 7
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DISCUSSION (PART 3) 
There is compelling evidence showing that HDL is cardioprotective and low 
HDL level is an independent risk factor of coronary artery disease (Assmann et al. 
2003). The cardioprotective mechanisms of HDL are complex and attributed to 
multiple biological functions beyond reverse-cholesterol transport (Nofer et al. 2002. 
Among other mechanisms, protective effects of HDL on endothelial function seem to 
play an important role (O’Connell et al. 2001, Assmann et al. 2003, Calabresi et al. 
2003). The vascular endothelial cells exert a wide spectrum of biological functions as 
diverse as the control of smooth muscle contraction, platelet aggregation, 
inflammation, as well as hemostasis (Yang et al. 2002). Alterations of one or more of 
the above-mentioned physiological roles constitute of endothelial dysfunction that is 
important in triggering cardiovascular events. Among other factors, TF is importantly 
involved in atherothrombosis (Ardissino et al. 1997, Moons et al. 2002, Suefuji et al. 
1997, Misumi et al. 1998, Annex et al. 1995, Wilcox et al. 1989, Marmur et al. 1996, 
Toschi et al. 1997). TF is up-regulated in atherosclerotic plaque and the plasma 
concentration of TF is increased in patients with unstable angina and myocardial 
infarction Suefuji et al. 1997, Misumi et al. 1998, Annex et al., 1995). Previous 
studies showed that thrombin up-regulates TF expression which is associated with an 
increased cell surface TF activity (Eto et al., 2002, Archipoff et al., 1991). This study 
further confirmed the stimulating effect of thrombin on TF expression. Most 
interestingly, the induction of endothelial TF expression by thrombin was 
significantly inhibited by rHDL. It is important to note that rHDL exerts similar 
biological functions as plasma HDL and intravenous infusion of rHDL restores HDL 
plasma concentration and improves endothelial function in ABCA1 heterozygote 
subjects with isolated low HDL level or in hypercholesterolemic patients (Spieker et 
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al., 2002, Bisoendial et al., 2003). The results of this study not only implicate a novel 
cardiovascular protective function of HDL, but also the therapeutic potential of rHDL 
in patients with coronary heart disease (Spieker et al., 2002, Bisoendial et al., 2003). 
Indeed, HDL isolated from human plasma, similar to rHDL, was also able to inhibit 
thrombin-induced endothelial TF expression. 
Although the regulatory mechanisms of endothelial TF expression have not 
been fully elucidated yet, recent research provides compelling evidence that RhoA 
and p38Pmapk P are important positive regulators of TF expression in endothelial cells 
(Eto et al., 2002, Ishibashi et al., 2003). In current study we demonstrated that 
adenoviral expression of an active RhoA mutant increased endothelial TF protein 
level, which further confirms the role of RhoA in up-regulating TF expression in 
endothelial cells (Eto et al., 2002, Ishibashi et al., 2003). Most interestingly, rHDL 
was able to inhibit thrombin-induced RhoA activation indicating that rHDL reduces 
endothelial TF expression by blocking RhoA activation. The mechanisms of RhoA 
inhibition by rHDL are unclear at this stage. Several possibilities could be postulated. 
Firstly, rHDL may inhibit upstream mechanisms of RhoA activation, such as guanine 
nucleotide exchange factors (GEFs) that transform the inactive RhoA.GDP to the 
active RhoA.GTP form, or inhibit GTPase-activating proteins (GAP) that return 
RhoA.GTP to the RhoA.GDP form, or rHDL may enhance activity of GDP-
dissociation inhibitor that prevents GDP dissociation from the GDP-bound form and 
keeps the small G-protein inactive. Secondly, rHDL may inhibit HMG-CoA reductase 
and thereby the production of HMG-CoA/mevalonate intermediates that are required 
for activation of RhoA (Takemoto et al., 2001). The above-mentioned hypotheses 
need further investigation. 
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The fact that TF up-regulation by thrombin was only partially inhibited by 
rHDL in spite of a full inhibition of RhoA suggests that other mechanism which up-
regulates TF expression may not be affected by rHDL. Several studies demonstrated 
the crucial role of p38PmapkP in TF upregulation in endothelial cells and monocytes (Eto 
et al., 2002, Blum et al., 2001, O’Reilly et al., 2003, Chu et al., 2001). In this study it 
was shown that p38PmapkP activation by thrombin remained unaffected by rHDL 
suggesting that rHDL inhibits endothelial TF expression via interfering with RhoA 
but not p38Pmapk P.  
While RhoA and p38Pmapk P positively regulate TF expression, PI3K/Akt pathway 
was shown to inhibit TF expression in human endothelial cells (Eto et al., 2002, Blum 
et al., 2001). In this study, rHDL activates Akt which is in line with the results of 
several other studies using plasma HDL (Mineo et al., 2003, Nofer et al., 2001). The 
effects of PI3K/Akt on thrombin-induced TF up-regulation in human endothelial cells 
were further investigated here. Two lines of evidence support a role of PI3K in the 
rHDL-mediated suppression of TF up-regulation by thrombin. Firstly, inhibition of 
PI3K by two different inhibitors wortmannin or LY-294002 reversed the effect of 
rHDL suggesting that rHDL inhibits TF up-regulation by thrombin via PI3K. It is to 
notice that wortmannin alone but not LY-294002, enhanced TF expression indicating 
that wortmannin may have certain non-specific effects not related to PI3K. Secondly, 
expression of an active PI3K mutant (rCD2-p110) reduced thrombin-stimulated TF 
expression (Figure. 5C). The function of the active PI3K in the cells was confirmed 
by the activation of Akt (phosphorylation of Akt at serine-473). Surprisingly, 
adenoviral expression of the active Akt mutant (m/p) enhanced thrombin-induced TF 
expression. Moreover, expression of a dominant negative Akt mutant (KA) reduced 
thrombin’s effect and did not reverse the rHDL’s inhibitory effect on TF expression 
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(Figure. 6D, panel b and c). These data suggest that PI3K reduces TF expression 
stimulated by thrombin not via Akt under the experimental condition. Activation of 
other downstream effectors of PI3K, which is independent of Akt, such as PKCξ, 
p70Ps6kP, protein tyrosin kinases (Tec family) and Rac47 or even some other yet to be 
identified effector(s) must play a dominant role in the inhibition of TF expression. 
Which of these downstream effector(s), that is dominant to Akt, accounts for the 
negative regulation of PI3K on TF expression, remains to be identified. These results 
contrast the observation by a recent study showing that expression of a constitutively 
active Akt mutant reduces VEGF-induced TF expression in human endothelial cells 
(Blum et al., 2001). The discrepancy between this study (Blum et al., 2001) and those 
obtained in our study remains obscure. It might be due to the different agents used for 
the stimulation of TF expression. VEGF was used in that study whereas thrombin was 
used as a stimulator of TF expression in this condition. It is noteworthy that neither 
the constitutively active Akt mutant nor the dominant negative mutant alone has any 
effect on basal TF expression, but they influence thrombin’s effect, i.e. the active Akt 
mutant facilitated and the negative Akt mutant reduced thrombin-induced endothelial 
TF up-regulation, suggesting that activation of Akt alone is not sufficient to modify 
TF expression and an interaction between Akt and thrombin-induced signalling 
mechanisms related to TF expression must exist, which may be different from that of 
Akt with VEGF. Hence, differential interaction between Akt and the signal 
transduction pathways stimulated by VEGF or thrombin may explain the different 
effect of active Akt on TF regulation.  
Activation of Akt affects cellular functions involving several downstream 
targets (Shiojima et al., 2002). In human endothelial cells, Akt phosphorylates eNOS 
at serine-1177 and enhances eNOS enzyme activity (Fulton et al., 1999, Dimmeler et 
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al., 1999, Ming et al., 2002). In line with the observation with plasma HDL (Mineo et 
al., 2003) we also showed in the current study that rHDL stimulates Akt and eNOS. 
The activation of Akt/eNOS could be abolished by PI3K inhibitor wortmannin. 
However, inhibition of eNOS by L-NAME did not affect the inhibitory effect of 
rHDL on thrombin-induced up-regulation of TF expression implicating that eNOS is 
not involved in the inhibition of endothelial TF expression by rHDL. This result 
further supports the conclusion that rHDL inhibits thrombin-induced endothelial TF 
expression through stimulation of PI3K but not Akt/eNOS. Similar observations were 
obtained in human endothelial cells stimulated with VEGF, a well-known eNOS 
stimulator (Blum et al., 2001). Indeed, VEGF-induced TF expression in the cells was 
not modified by L-NAME (Blum et al., 2001). These results contrast with the 
observations in macrophages and endothelial cells when stimulated with endotoxin or 
IL-1β (Perez-Ruiz et al., 2002, Yang et al., 2000, Corseaux et al., 1998), where NO is 
implicated in suppression of TF expression. The discrepancy between this study and 
those studies may be explained by the fact that large amounts of NO are released from 
iNOS in macrophages or endothelial cells stimulated with endotoxin, whereas 
stimulation of eNOS by rHDL is relatively weak that is not sufficient to inhibit TF 
expression under this experimental condition. Moreover, in the experiments where L-
arginine was supplemented to enhance NO production, an inhibition of TF production 
was observed (Yang et al., 2000, Corseaux et al., 1998). However, a non-NO-
mediated role for L-arginine in modulating TF expression cannot be excluded with 
complete certainty (Loscalzo J, 2000).  
A recent study by Gratton demonstrated that adenoviral expression of a 
constitutively active Akt in endothelial cells causes inactivating phosphorylation of 
MEKK3 which leads to subsequential inhibition of MKK3/MKK6-p38Pmapk P pathway, 
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and conversely dominant negative Akt mutant decreases inactivating phosphorylation 
of MEKK3 and therefore, enhances MKK-p38Pmapk P activation in response to VEGF 
(Gratton et al., 2001), suggesting a negative regulation of p38Pmapk P pathway by 
PI3K/Akt pathway. This mechanism, however, does not account for the inhibition of 
thrombin-induced TF expression by rHDL, since p38Pmapk P activation by thrombin was 
not affected by rHDL (Figure. 3). The possibility that rHDL reduces thrombin-
induced endothelial TF expression via interfering RhoA activation by PI3K can also 
be excluded, since adenoviral expression of a constitutively active PI3K mutant did 
not inhibit thrombin-induced RhoA activation in the cells (Figure. 7).  
 
 
 
 
 
 
Figure 8: Schematic diagram showing mechanisms of inhibition of endothelial tissue factor 
expression by HDL. 
Conversely, active RhoA did not interfere with PI3K activity as reported in a 
previous study (Ming et al., 2002). Therefore, both inhibition of RhoA and activation 
of PI3K contribute to the suppression of thrombin-induced TF expression by rHDL. 
The inhibition of RhoA by rHDL can also explain the result presented on Figure. 6 
showing that rHDL reversed thrombin’s inhibitory effect on Akt activation, since 
RhoA activation induced by thrombin inactivates Akt in the cells as demonstrated by 
a previous study (Ming et al., 2002).  
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In conclusion, rHDL inhibits thrombin-induced TF up-regulation via inhibition 
of RhoA and stimulation of PI3K but not Akt/eNOS (Figure. 8). This finding may 
represent a novel atherosprotective mechanism of HDL in clinical settings and 
implicate the therapeutic potential rHDL in coronary artery disease. 
________________________________________________________________________Conclusions 
 
 116 
IV. CONCLUSIONS 
Taken all the results together, we conclude that Rho/ROCK pathway is 
activated under atherogenic stimuli, which plays multiple roles in the regulation of 
endothelial cell function at several levels (details, see Figure 9).  
Figure 9: The multiple roles of RhoA/ROCK pathway in endothelial dysfunction. Atherogenic 
stimulants activate Rho/ROCK pathway which decreases endothelial NO production via 
destabilizing eNOS mRNA (1) and inhibiting eNOS enzyme activation through blockade of 
PKB/Akt (2). Moreover, Rho/ROCK increases arginase activity, which metabolizes L-arginine to 
urae and ornithine, thereby further decreasing NO production by depletion of the eNOS 
substrate, L-arginine in the cells (3). Activation of the Rho/ROCK pathway also upregulates 
tissue factor expression in endothelial cells (4). This effect of Rho/ROCK could be prevented by 
HDL (5). In addition, HDL suppresses endothelial tissue factor expression via PI3K (6), 
independent of Akt/PKB/eNOS cascade (7). Activation of the PI3K/PKB/eNOS pathway by HDL 
leads to an enhanced NO production.   
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